

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

Patient preferences for drug therapy in inflammatory arthritis: protocol for a living systematic review and evidence map to inform clinical practice guidelines

Journal:	BMJ Open
Manuscript ID	bmjopen-2024-088267
Article Type:	Protocol
Date Submitted by the Author:	01-May-2024
Complete List of Authors:	Saadat, Pakeezah; University of Toronto Bansback, Nick; The University of British Columbia Falahee, Marie; University of Birmingham Hiligsmann , Mickaël ; Maastricht University, Department of Health Services Research Tugwell, Peter; University of Ottawa Faculty of Medicine, Department of Medicine Buchbinder, Rachelle; Monash University Whittle, Samuel; Monash University Richards, Dawn P.; Canadian Arthritis Patient Alliance Proulx, Laurie ; Canadian Arthritis Patient Alliance Schunemann, Holger; Hamilton, Department of Health Research Methods, Evidence and Impact; Hamilton, Department of Medicine Alonso-Coello, Pablo; Instituto de Investigacion Biomedica Nieuwlaat, Robby; Hamilton, Department of Medicine; Hamilton Wiercioch, Wojtek; Hamilton, Department of Medicine; Hamilton Kuper, Simon; Maastricht University Pardo Pardo, Jordi; University of Ottawa Hazlewood, Glen; University of Calgary, Departments of Medicine and Community Health Sciences
Keywords:	Patients, RHEUMATOLOGY, Systematic Review



1	
2	
3 4	Patient preferences for drug therapy in inflammatory arthritis: protocol for a living systematic
5	
6	review and evidence map to inform clinical practice guidelines
7	
8	Pakeezah Saadat, ¹ pakeezah.saadat@mail.utoronto.ca
9	Nick Bansback, ² nick.bansback@ubc.ca
10	Marie Falahee, ³ m.falahee@bham.ac.uk
11	Mickael Hiligsmann, ⁴ m.hiligsmann@maastrichtuniversity.nl
12	Peter Tugwell, ⁵ ptugwell@uottawa.ca
13 14	Rachelle Buchbinder, ⁶ rachelle.buchbinder@monash.edu
14	Samuel Whittle, ⁷ samuelwhittle@gmail.com
16	Dawn P Richards, ⁸ dawn.p.richards@gmail.com
17	Laurie Proulx, ⁸ laurieproulx@bell.net
18	Holger Schunemann, ^{9,10} holger.schunemann@mcmaster.ca
19	Pablo Alonso Coello, ¹¹ palonso@santpau.cat
20	Robby Nieuwlaat, ^{10,12} <u>nieuwlr@mcmaster.ca</u>
21	Wojtek Wiercioch, ^{10,12} wierciww@mcmaster.ca
22	Simon Kuper, ¹³ simon.kuper97@gmail.com
23	Jordi Pardo Pardo, ¹⁴ jpardo@uottawa.ca
24 25	Glen S Hazlewood ¹⁵ gshazlew@ucalgary.ca
25	Gien S haziewood gshaziew@ucaigary.ca
27	¹ Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada
28	² School of Population and Public Health, University of British Columbia, BC, Canada; Arthritis Research
29	
30	Canada, Richmond, BC, Canada ³ Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental
31	
32	Sciences, University of Birmingham, Birmingham, UK; NIHR Birmingham Biomedical Research Centre,
33	University Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, UK
34 25	⁴ Department of Health Services Research, CAPHRI Care and Public Health research Institute, Maastricht
35 36	University, Netherlands
37	⁵ Department of Medicine, University of Ottawa Faculty of Medicine, Ottawa, ON, Canada; Clinical
38	Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada
39	⁶ Musculoskeletal Health and Wiser Health Care Units, School of Public Health and Preventive Medicine,
40	Monash University, Melbourne, Australia
41	⁷ School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia;
42	Rheumatology Unit, Queen Elizabeth Hospital, Adelaide, Australia
43	⁸ Canadian Arthritis Patient Alliance, Toronto, ON, Canada
44 45	⁹ Department of Health Research Methods, Evidence and Impact, McMaster University, Health Sciences
45 46	Centre, Hamilton, ON, Canada
47	¹⁰ Department of Medicine, McMaster University, Health Sciences Centre, Hamilton, ON L8S 4K1,
48	Canada; Department of Biomedical Sciences, Humanitas University, Milano, Italy
49	¹¹ Centro GRADE Barcelona, Instituto de Investigacion Biomedica (IIB Sant Pau), Barcelona, Spain
50	¹² World Health Organization Collaborating Center for Infectious Diseases, Research Methods and
51	Recommendations, Michael G. DeGroote Cochrane Canada & McMaster GRADE Centres; McMaster
52	University, Hamilton, ON, Canada
53	¹³ Faculty of Health, Medicine and Life Sciences, Maastricht University, Germany
54	¹⁴ Cochrane Musculoskeletal, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
55 56	
56 57	
57	1
59	1
60	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

¹⁵Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada; Arthritis Research Canada, Richmond, BC, Canada; McCaig Institute for Bone and Joint Health, Calgary, Canada

Corresponding Author:

Glen S Hazlewood, gshazlew@ucalgary.ca

3280 Hospital Dr NW 3AA10 HRIC Calgary AB T2N4Z6 Canada

Competing interests:

Pakeezah Saadat: None relevant to the content of this study. Nick Bansback: None relevant to the content of this study. Marie Falahee: None relevant to the content of this study. Mickael Hiligsmann: None relevant to the content of this study. Peter Tugwell: None relevant to the content of this study. Rachelle Buchbinder: None relevant to the content of this study. Samuel Whittle: None relevant to the content of this study. Dawn Richards: None relevant to the content of this study. Laurie Proulx: None relevant to the content of this study. Holger Schunemann: None relevant to the content of this study. Pablo Alonso Coello: None relevant to the content of this study. Robby Nieuwlaat: None relevant to the content of this study. Wojtek Wiercioch: None relevant to the content of this study. Simon Kuper: None relevant to the content of this study. Jordi Pardo Pardo: None relevant to the content of this study. Glen S Hazlewood: None relevant to the content of this study. Word count: 2151

ABSTRACT

Introduction: The pharmacological management of inflammatory arthritis often requires individuals to make choices that involve trade-offs. These choices entail selecting treatments with varying benefits, risks, and other attributes such as administration route, frequency and cost. This living systematic review aims to inform international clinical guidelines on inflammatory arthritis by creating an evidence map of patient preference studies concerning the trade-offs in pharmacological management of inflammatory arthritis.

Methods and analysis: We will search Medline and EMBASE for any published and peerreviewed full-text studies that quantitatively assess preferences of patients for the pharmacological management of inflammatory arthritis. Two independent reviewers will perform abstract and full-text screening. Studies that utilize either stated- or revealedpreference methods to assess preferences and provide a quantitative assessment of relevant characteristics, such as benefits, risks, costs, and process attributes, will be included. Risk of bias will be assessed using the GRADE risk of bias tool. An evidence map will be generated to summarize included studies and their assessments of each trade-off. The search will be conducted every 6 months with new studies added to the inventory.

Ethics and dissemination: This study does not require ethics approval. Findings from this study will be disseminated widely to relevant stakeholders via conference presentations, journal publications, and will also be made accessible on an Open Access website.

Key words: inflammatory arthritis, patient preference, trade-off, living systematic review **Word count**: 215

BMJ Open: first published as 10.1136/bmjopen-2024-088267 on 15 January 2025. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de Enseignement Superieur (ABES)

Enseignement Superieur (ABES). Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

BMJ Open: first published as 10.1136/bmjopen-2024-088267 on 15 January 2025. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

STRENGTHS AND LIMITATIONS OF THIS STUDY

- This living systematic review of patient preference studies will inform international • clinical guidelines for inflammatory arthritis.
- Biannual updates will be conducted to promptly integrate emerging evidence, facilitating the maintenance of up-to-date clinical guidelines for inflammatory arthritis.
- Since the field is still evolving, the search strategy and data presentation will be adapted • to incorporate newly emerging evidence.
- We will not meta-analyze the relative importance of each attribute as quantitative synthesis poses a challenge due to significant heterogeneity in study designs and attributes.

INTRODUCTION

Treatment choices in inflammatory arthritis nearly always involve trade-offs. People living with inflammatory arthritis need to choose between treatments that can differ in their benefits, risks, and other characteristics such as route of administration, frequency, and cost. For example, in rheumatoid arthritis, "triple therapy" with methotrexate, sulfasalazine and hydroxychloroquine has additional burden in terms of more pills, potentially more adverse effects, but an improved chance of a treatment response over methotrexate alone ¹². Tofacitinib, a JAK inhibitor, has been shown to have a higher risk of cardiovascular adverse events and certain malignancies in people at risk for cardiovascular events ³, but is available as a pill and is an effective option for many patients. For people with psoriatic arthritis, certain treatments may work better for different disease manifestations, such as skin disease or enthesitis, and this needs to be balanced against the control of their joint disease ⁴⁵. Corticosteroids offer rapid improvement for many patients with inflammatory arthritis, but long-term use is associated with multiple risks ⁶.

Patient preferences can be assessed or measured in multiple ways. Qualitative approaches can help understand how patients approach the decision-making process and the relevant considerations for a given healthcare decision ⁷. Quantitative approaches provide numerical estimates of patient preferences for different treatments or treatment attributes, including risks and benefits and other considerations, such as route of administration or cost ⁸⁹. Quantitative methods can be categorized into revealed preference methods that measure which treatment people choose when presented with an actual choice, or stated preference methods that ask patients to rate, rank, or choose between hypothetical treatment options or

BMJ Open: first published as 10.1136/bmjopen-2024-088267 on 15 January 2025. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de Enseignement Superieur (ABES)

Enseignement Superieur (ABES). Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

attributes. Stated preference methods can be further categorized according to different frameworks ^{8 10}. Revealed preference methods, where actual choices of participants are recorded are challenging, as real-world choices are often influenced by the healthcare providers' recommendations or restrictions imposed by insurance plans. Hence, most studies use stated preference methods.

When developing clinical practice guidelines, it is important to understand patient preferences for the relevant trade-offs. Under the GRADE approach, patient values and preferences are a key consideration in the Evidence to Decision framework, when deciding on the direction and strength of a recommendation ¹¹. While not often done, a systematic review of patient preference studies is recommended to inform these judgements ¹². Quantitative estimates of patient preferences are desired, as guideline panels need to consider which outcomes or other attributes are most important and by how much. When a guideline panel is confident that based on the balance of benefits and harms nearly all patients would choose a particular course of action then a strong recommendation can be made. Otherwise, a conditional recommendation is made, either for or against the treatment.

We have recently started living clinical guidelines for inflammatory arthritis in both Canada ^{13 14} and Australia ¹⁵⁻¹⁷. In a living clinical practice guideline, treatment recommendations are kept up to date as new evidence emerges ¹⁸. Within an entire guideline, individual recommendations may remain stable, whereas others may be updated in a living mode through living systematic reviews of the risks and benefits, which we have initiated for inflammatory arthritis ¹⁹. Each time a recommendation is added, or new evidence emerges, guideline panels need to either make or update their judgements regarding the balance of risks and benefits. In a living model,

this requires regular updates of the evidence on patient preferences. New preference studies may have been published, and treatments may have new attributes, such as newly discovered risks. For example, in our inflammatory arthritis guidelines, our recommendation for choices of treatment after an inadequate response to anti-TNF therapy ^{14 15} required an update to our prior systematic review on patient preferences ^{20 21}, given the risks of malignancy and cardiovascular events with JAK inhibitors. We did not find any studies that measured preferences for these trade-offs, but this evidence will likely emerge over time. The aim of this systematic review will be to develop a living evidence map of patient preference studies as they relate to the treatment of inflammatory arthritis. By "evidence map" we mean a catalogue of studies that are characterized in terms of their characteristics and methods used, risk of bias, and which outcomes or other treatment attributes they included. We do not intend to summarize or meta-analyze the relative importance of each attribute, which is often challenging due to study heterogeneity. Rather, the intention is that guideline developers can use the evidence map to identify and review the studies relevant to their context to help inform clinical guideline recommendations.

METHODS

This protocol adheres to the PRISMA-P checklist²².

Eligibility criteria

Population

We will include any study that provides a quantitative assessment of patients' preferences for the management of inflammatory arthritis. Inflammatory arthritis includes rheumatoid arthritis, BMJ Open: first published as 10.1136/bmjopen-2024-088267 on 15 January 2025. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) .

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

BMJ Open: first published as 10.1136/bmjopen-2024-088267 on 15 January 2025. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de Enseignement Superieur (ABES)

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

juvenile idiopathic arthritis, and spondyloarthritis, as defined by the study authors. Spondyloarthritis includes psoriatic arthritis, ankylosing spondylitis, reactive arthritis, enteropathic arthritis, and axial and/or peripheral spondyloarthritis not otherwise classified. We will include studies that have at least 75% of the included participants with inflammatory arthritis.

Outcomes

To be included, a study must include a quantitative assessment of the importance of attributes relevant to the pharmacologic and non-pharmacologic management of inflammatory arthritis. This includes treatment benefits, risks, and process attributes. Process attributes include any aspect related to care delivery, such as route and frequency of administration, access to care, and costs. Preferences may be assessed for attributes separately, or together, as would be the case when presenting patients with a 'real-world' choice between treatment options that differ across multiple characteristics (i.e., in revealed preference studies). We will exclude studies that exclusively provide an estimate of patients' health-related quality of life (HRQOL). HRQOL measures the value a patient places on their current health state and not their preference for potential treatment outcomes or attributes ^{23 24}.

Study design

We will include any published and peer-reviewed full-text study in any language that assessed preferences using stated-preference methods ¹⁰ (where participants are asked their preferences for hypothetical choices) or revealed-preference methods (where the actual choices of patients are observed after being presented with a decision-aid) ⁸. The stated-preference methods categorized by Soekhai et al. ¹⁰ consist of four distinct categories (**Table 1**).

Discrete-choice experiments examine trade-offs between attributes and their alternatives given a series of choice sets. Ranking methods are used to elicit an order of attributes and their alternatives through ranking exercises, such as best-worst scaling. Indifference methods, such as time trade-off or standard gamble, manipulate attribute values until the participant is indifferent, or has no preference. Rating methods ask people to choose the strength of their preference using a labeled scale. We will exclude abstracts, pre-print articles and studies that Ved. have not been peer-reviewed.

BMJ Open: first published as 10.1136/bmjopen-2024-088267 on 15 January 2025. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES). Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

 Table 1. Inventory of patient-preference methods, adapted from Soekhai et al. ¹⁰

Category	Method
Discrete-choice-based methods	Discrete choice experiment/Best-worst scaling (type 3)
	Adaptive conjoint analysis
Ranking methods	Qualitative discriminant process
	Q-methodology
	Control preferences scale
	Best-worst scaling (type 1 & 2)
•	Self-explicated conjoint
Indifference methods	Standard gamble
	Time trade-off
0.	Person trade-off
	Starting known efficacy
	Test trade-off
	(Probabilistic) threshold technique
	Contingent valuation
Rating methods	Constant sum scaling
	Repertory grid method
	Analytic hierarchy process
	Swing weighting
	Visual analog scale
	Allocation of points
	Outcome prioritization tool
	Measure of value
Revealed preferences	Patient preference trials
	Direct questions in clinical trials

Living review considerations: If new preference-based approaches are identified or developed over time, these will be added to the eligibility criteria. Our search (described below) is also designed to identify qualitative studies, which would allow us to expand the scope of work in the future.

Information sources and search strategy

We will search the following databases from inception: Medline In Process and Other Nonindexed Citations, and EMBASE (Excerta Medica Database). The search strategy is presented in **Appendix A** and combines keywords and subject headings for inflammatory arthritis and preference-based methods. The MEDLINE and EMBASE inflammatory arthritis filters were derived from Cochrane reviews and adapted for the other databases. The preference-based method filter was derived from Selva et al ²⁵ and supplemented with additional filters to capture all methods in Table 1, as well as qualitative studies. Additionally, we will search the Health Preference Study and Technology Registry (HPSTR; <u>https://hpstr.org/</u>), a web-based registry of health preference studies and technologies, using keywords for each population of interest (defined above).

Living review considerations: The search filters will be reviewed periodically and updated as needed, particularly if new validated filters for preference studies are published that suit our purpose. For the base review, the search will be conducted once, then updated prior to publication, after which the review will transition to a living mode. In the living mode, the search will be updated every 6 months, with the frequency adjusted as needed based on the usefulness and feasibility.

Article screening

The titles and abstracts of all records will first be screened for eligibility independently by two reviewers. Any record that either reviewer marks as unclear or included will proceed to full-text review. Full-text review will also be done by pairs of reviewers working independently. Any disagreement at the full-text stage will be discussed between reviewers and with senior reviewer(s) as necessary. At the full-text stage, articles will be excluded in the following BMJ Open: first published as 10.1136/bmjopen-2024-088267 on 15 January 2025. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) .

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

BMJ Open: first published as 10.1136/bmjopen-2024-088267 on 15 January 2025. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

hierarchy: wrong publication type (e.g. pre-print, abstract); wrong population; wrong study design (not a preference-elicitation method); preferences for other aspects of care (e.g., diagnostic approaches). Articles in a different language will be translated into English. An example PRISMA flow-chart is presented in **Figure 1**.

Living review considerations: We will explore the incorporation of technologies to improve the efficiency of the article screening process, including automation, machine learning and crowd sourcing. We have employed these tools in other reviews of interventions ¹⁹ ²⁶, but to our knowledge they have not yet been developed for patient preference literature. It is our hope that the results of our review could be used to develop automated approaches for the screening of records. We will flag potentially eligible qualitative studies in the correct population, which would allow us to expand the scope of work in the future without having to rescreen all records.

Data extraction

Study data will be extracted independently by two team members. From each study we will extract relevant study and participant characteristics as listed in **Appendix B** if reported. Study characteristics include details on the population of interest, setting, response rate, recruitment strategy, funding, statistical analysis used, attribute selection process, and preference-elicitation methods. Participant characteristics include age, sex/gender, disease duration and severity, health literacy and sociodemographic characteristics, particularly those that would identify patient populations at risk for inequities in care. In prior studies, we have identified the following seven priority populations for guidelines in rheumatoid arthritis ^{27 28}: rural and remote residents, Indigenous Peoples, elderly persons with frailty, first-generation immigrants and

Page 13 of 28

BMJ Open

refugees, persons of low socioeconomic status or who are vulnerably housed, sex and gender diverse populations, and Black Canadians (added since our original framework²⁹). For each study, we will extract the attributes and levels evaluated, including a short description and the actual description presented in the survey to participants. The results of the study will be extracted as the estimated value for each attribute value, including the point estimate (mean/median), scale, and measure of variability. If this data is not presented it will calculate from the available data, if possible. Otherwise, we will extract the data as reported by the study (e.g. relative importance, ranks of attribute importance). We will extract measures of variability in the following order depending on availability: standard deviations (SDs), standard errors (SEs), 95% confidence intervals (Cis) or credible intervals (CrI), and exact P-values with the statistical test used. Data screening and extraction will be done via Covidence systematic review software (Veritas Health Innovation, Melbourne, Australia, available at www.covidence.org). Living review considerations: Depending on the volume of studies identified, the timing of data extraction for each study may need to be staged, prioritizing those studies that are most relevant to inform our living guidelines. We will include a table of studies pending data extraction and risk of bias assessment in the review.

<u>Risk of bias</u>

The risk of bias in each study will be assessed using the GRADE risk of bias tool for value and preference studies, which has been developed and validated, and is being finalized for publication. Assessment will be done independently by two team members and any discrepancies will be resolved through consensus.

BMJ Open: first published as 10.1136/bmjopen-2024-088267 on 15 January 2025. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de Enseignement Superieur (ABES)

Enseignement Superieur (ABES). Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

Living review considerations: If preferred risk of bias tools change over time, these will be incorporated in the review.

Data presentation

Study characteristics will be summarized descriptively in a table. An evidence map will be generated that summarizes the current literature in terms of which available studies assess each trade-off. An example is included in **Table 2**. The rows and columns will contain all attributes assessed. Attributes will be grouped into categories by two independent reviewers with help from a senior reviewer, if needed. Each cell will list the study(s) that included those attributes. Studies that include absolute anchors of attribute importance, such as a standard gamble, time trade-off or visual analogue scales, will be included in the bottom row. This would allow guideline panels to easily identify potential studies that would be relevant for their purpose and help identify gaps in the evidence.

Living review considerations: We will explore the value of including additional information within each cell of the evidence map (e.g., sample size and risk of bias), and alternative ways of summarizing the data to guideline panels, including interactive evidence maps that would provide more flexibility.

Page 15 of 28

		Benef	its			Risks			di o Process		
		Remission	Pain reduction	Prevention of joint damage	GI side effects	Serious side effects	Injection site reaction	Route of delivery	Freguency	Cost	
Benefits	Remission	-	-	-	-	-	-	- u	ary 2	-	
Ben	Pain reduction	[Study IDs]	-	-	-	-	-	- 4	025.	-	
	Prevention of joint	[Study IDs]	[Study IDs]	-	-	-	-	- 10		-	
	damage								nload		
	GI side effects	[Study IDs]	[Study IDs]	[Study IDs]	-	-	-		eur (/	-	
s	Serious side effects	[Study IDs]	[Study IDs]	[Study IDs]	[Study IDs]	-	-	-		-	
Risks	Injection site reaction	[Study IDs]	[Study IDs]	[Study IDs]	[Study IDs]	[Study IDs]	-	- ų,	ttp://bm	-	
s	Route of delivery	[Study IDs]	[Study IDs]	[Study IDs]	[Study IDs]	[Study IDs]	[Study IDs]	ه [Study IDs] پو	6/bmjopen-2024-088267 on 1@uency Frocess From the set of the set o	-	
Process	Frequency	[Study IDs]	[Study IDs]	[Study IDs]	[Study IDs]	[Study IDs]	[Study IDs]	[Study IDs]	tudy IDs]	-	
_	Cost	[Study IDs]	[Study IDs]	[Study IDs]	[Study IDs]	[Study IDs]	[Study IDs]	[Study IDs]		-	
	Absolute anchor of importance	[Study IDs]	[Study IDs]	[Study IDs]	[Study IDs]	[Study IDs]	[Study IDs]	[Study IDs]	June 13, 2025 at Agence Bibliographique de I	[Study IDs	

Patient and Public Involvement:

This protocol was reviewed and refined with feedback from our patient partners, Dawn P Richards and Laurie Proulx, who are individuals living with rheumatoid arthritis/juvenile idiopathic arthritis.

Ethics and dissemination

Ethics approval is not required. Results from the base review will be published in a peerreviewed journal. In the living model, we will publish updates and datasets on an Open Science Framework page with periodic updates in peer-reviewed journals.

Author contributions

GSH is the guarantor. GSH conceptualized the study, and designed and reviewed the protocol with PS. PS and GSH drafted the study, defined the concepts, search strategy, data extraction process, methodological appraisal, and statistical analysis of the included studies. NB, MF, MH, PT, RB, SW, DR, LP, HS, PAC, RB, WW, SK, and JPP provided critical insights. All authors have approved and contributed to the final written manuscript.

Funding statement

This protocol received no specific grant from any funding agency in the public, commercial or not-for-profit sectors. Funding is being sought for the review.

RB is supported by an Australian National Health and Medical Research Council (NHMRC) Investigator Fellowship (APP1194483). SW is supported by an Australia and New Zealand Musculoskeletal (ANZMUSC) Clinical Trial Network Practitioner Fellowship and by a grant from The Hospital Research Foundation Group. REFERENCES

2016/04/23]

2016/08/30

First: 2018/12/01]

2023.

[published Online First: 2022/01/27]

[published Online First: 2022/06/28]

1

1. Hazlewood GS, Barnabe C, Tomlinson G, et al. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-

analysis. BMJ 2016;353:i1777. doi: 10.1136/bmj.i1777 [published Online First:

3. Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and Cancer Risk with Tofacitinib in

4. Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and

6. Rice JB, White AG, Scarpati LM, et al. Long-term Systemic Corticosteroid Exposure: A

7. Gooberman-Hill R. Qualitative approaches to understanding patient preferences. Patient 2012;5(4):215-23. doi: 10.1007/BF03262494 [published Online First: 2012/09/26] 8. Medical device Innovation Consortium (MDIC). Medical device Innovation Consortium (MDIC)

Systematic Literature Review. Clin Ther 2017;39(11):2216-29. doi: 10.1016/j.clinthera.2017.09.011 [published Online First: 2017/10/23]

5. Singh JA, Guyatt G, Ogdie A, et al. Special Article: 2018 American College of

2021. Nat Rev Rheumatol 2022;18(8):465-79. doi: 10.1038/s41584-022-00798-0

Rheumatoid Arthritis. N Engl J Med 2022;386(4):316-26. doi: 10.1056/NEJMoa2109927

Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis

Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Rheumatol 2019;71(1):5-32. doi: 10.1002/art.40726 [published Online

2. Hazlewood GS, Barnabe C, Tomlinson G, et al. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis. Cochrane Database Syst Rev 2016(8):CD010227. doi: 10.1002/14651858.CD010227.pub2 [published Online First:

1 2	
2 3	
3 4 5 6 7 8 9	
5	
6	
7	
8	
9 10	
11	
12	
13	
14	
12 13 14 15 16	
16 17	
18	
18 19	
20	
20 21 22 23 24 25 26 27 28 29 30 31	
22	
23	
24	
26	
27	
28	
29	
30 31	
32	
33 34	
34	
35 36	
36 37	
38	
39	
40	
41	
42 43	
45 44	
45	
46	
47	
48	
49 50	
50 51	
52	
53	
54	
55	
56 57	
58	
59	
60	

Patient Centered Benefit-Risk Project Report: A Framework for Incorporating Information on Patient Preferences Regarding Benefit and Risk into Regulatory Assessments of New Medical Technology 2015 [updated March 11, 2022. Available] from: https://mdic.org/project/patient-centered-benefit-risk-pcbr/ accessed 5 Sept 9. Hazlewood GS. Measuring Patient Preferences: An Overview of Methods with a Focus on Discrete Choice Experiments. Rheumatic Diseases Clinics of North America 2018;44(2):337-47. doi: https://dx.doi.org/10.1016/j.rdc.2018.01.009 10. Soekhai V, Whichello C, Levitan B, et al. Methods for exploring and eliciting patient preferences in the medical product lifecycle: a literature review. Drug Discov Today 2019;24(7):1324-31. doi: 10.1016/j.drudis.2019.05.001 [published Online First: 2019/05/12] 11. Montori VM, Brito JP, Murad MH. The optimal practice of evidence-based medicine: incorporating patient preferences in practice guidelines. JAMA 2013;310(23):2503-4. doi: 10.1001/jama.2013.281422 [published Online First: 2013/10/30] For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

 Andrews JC, Schunemann HJ, Oxman AD, et al. GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength. J Clin Epidemiol 2013;66(7):726-35. doi: 10.1016/j.jclinepi.2013.02.003 [published Online First: 2013/04/11]

1 2 3

4

5

6 7

8

9

10

11

12 13

14

15

16

17

18 19

20

21

22

23 24

25

26

27

28

29 30

31

32

33

34 35

36

37

38

39

40 41

42

43

44

45 46

47

48

49

50

51 52

53

54

55 56 57

58 59


- 13. Hazlewood GS, Pardo JP, Barnabe C, et al. Canadian Rheumatology Association living guidelines for the pharmacological management of rheumatoid arthritis with diseasemodifying anti-rheumatic drugs. *Journal of Rheumatology* 2022;15:15. doi: <u>https://dx.doi.org/10.3899/jrheum.220209</u>
- 14. Hazlewood GS, Pardo JP, Barnabe C, et al. Canadian Rheumatology Association living guidelines for the pharmacological management of rheumatoid arthritis with disease-modifying anti-rheumatic drugs 2022 [version 1.0] [Available from: https://app.magicapp.org/#/guideline/6511 accessed June 16, 2023 [version 1.0].
- 15. Australia & New Zealand Musculoskeletal Clinical Trials Network (ANZMUSC). An Australian Living Guideline for the Pharmacological Management of Inflammatory Arthritis 2023 [version 2.14] [Available from: https://app.magicapp.org/#/guideline/LqRV3n accessed June 16 2023 [version 2.14].
- 16. Buchbinder R, Glennon V, Johnston RV, et al. Australian recommendations on perioperative use of disease-modifying anti-rheumatic drugs in people with inflammatory arthritis undergoing elective surgery. *Intern Med J* 2023 doi: 10.1111/imj.16073 [published Online First: 2023/04/18]
- Whittle SL, Glennon V, Johnston RV, et al. Australian recommendations on tapering of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in inflammatory arthritis. *Intern Med J* 2022;52(10):1799-805. doi: 10.1111/imj.15816 [published Online First: 2022/05/15]
- El Mikati IK, Khabsa J, Harb T, et al. A Framework for the Development of Living Practice Guidelines in Health Care. Ann Intern Med 2022;175(8):1154-60. doi: 10.7326/M22-0514 [published Online First: 2022/07/06]
- 19. Hazlewood GS, Whittle SL, Kamso MM, et al. Disease-modifying anti-rheumatic drugs for rheumatoid arthritis: a systematic review and network meta-analysis. *Cochrane Database of Systematic Reviews* 2020(3) doi: 10.1002/14651858.CD013562
- 20. Simons G, Caplan J, DiSantostefano RL, et al. Systematic review of quantitative preference studies of treatments for rheumatoid arthritis among patients and at-risk populations. *Arthritis Res Ther* 2022;24(1):55. doi: 10.1186/s13075-021-02707-4 [published Online First: 2022/02/24]
- 21. Durand C, Eldoma M, Marshall DA, et al. Patient Preferences for Disease-modifying Antirheumatic Drug Treatment in Rheumatoid Arthritis: A Systematic Review. *Journal of Rheumatology* 2020;47(2):176-87. doi: 10.3899/jrheum.181165
- Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;4(1):1. doi: 10.1186/2046-4053-4-1 [published Online First: 2015/01/03]
- 23. Purnell TS, Joy S, Little E, et al. Patient preferences for noninsulin diabetes medications: a systematic review. *Diabetes Care* 2014;37(7):2055-62. doi: 10.2337/dc13-2527 [published Online First: 2014/06/26]

24. Hazlewood GS. Measuring Patient Preferences: An Overview of Methods with a Focus on
Discrete Choice Experiments. Rheum Dis Clin North Am 2018;44(2):337-47. doi:
10.1016/j.rdc.2018.01.009 [published Online First: 2018/04/07]

- 25. Selva A, Sola I, Zhang Y, et al. Development and use of a content search strategy for retrieving studies on patients' views and preferences. *Health Qual Life Outcomes* 2017;15(1):126. doi: 10.1186/s12955-017-0698-5 [published Online First: 2017/08/31]
- 26. Lee C, Thomas M, Ejaredar M, et al. Crowdsourcing trainees in a living systematic review provided valuable experiential learning opportunities: a mixed-methods study. J Clin Epidemiol 2022;147:142-50. doi: 10.1016/j.jclinepi.2022.03.019 [published Online First: 2022/04/02]
- 27. Pianarosa E, Hsiao R, Thomas M, et al. Supporting Equity Through Rheumatoid Arthritis Treatment Guidelines: The Development of Logic Models for Six Populations at Risk for Inequitable Outcomes in Canada. *Journal of Rheumatology* 2020;47(7):1083-84.
- Barnabe C, Pianarosa E, Hazlewood G. Informing the GRADE evidence to decision process with health equity considerations: demonstration from the Canadian rheumatoid arthritis care context. *J Clin Epidemiol* 2021;138:147-55. doi: 10.1016/j.jclinepi.2021.06.013 [published Online First: 2021/06/24]
- 29. Thomas M, Barnabe C, Kleissen T, et al. Rheumatoid Arthritis Care Experiences of Black People Living in Canada: A Qualitative Study to Inform Health Service Improvements. *Arthritis Care Res (Hoboken)* 2023 doi: 10.1002/acr.25278 [published Online First: 2023/12/11]

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

PRISMA 2020 flow diagram for new systematic reviews which included searches of databases and registers only






Figure 1. PRISMA flow diagram for the living systematic review of patient preference studies in inflammatory

arthritis

Appendix A. MEDLINE Search strategy (adapted from Selva et al, 2017)¹

#	Query
1	exp arthritis, rheumatoid/
2	((rheumatoid or reumatoid or revmatoid or rheumatic or reumatic or revmatic or rheumat* or reumat* or revmarthrit*) adj3 (arthrit* or artrit* or diseas* or condition* or nodule*)).tw.
3	1 or 2
4	exp Arthritis, Juvenile Rheumatoid/
5	JIA.tw
5	(juvenile adj2 arthritis).tw.
7	or/4-6
3	enthesitis.tw.
)	Arthritis, Psoriatic/
10	oligoarthritis.tw.
11	or/8-10
12	(child* or adolescent* or infan*).tw.
13	11 and 12
14	limit 11 to (infant or child or preschool child <1 to 6 years> or school child <7 to 12
	years> or adolescent <13 to 17 years>)
15	13 or 14
16	Spondylarthritis/
17	spondylarthritis.ti,ab.
18	spondyloarthritis.ti,ab.
19	Spondylarthropathies/
20	spondylarthropath\$.ti,ab.
21	spondyloarthropath\$.ti,ab.
22	Spondylitis/
23	Spondylitis, Ankylosing/
24	ankylosing spondylitis.ti,ab.
25	spondylitis.ti,ab.
26	((axial adj (SpA or disease or arthritis)) or axial joint disease).ti,ab.
27	enthesitis.ti,ab.
28	sacroiliitis/ or (sacroiliitis or sacroilitis).ti,ab.
29	(peripheral adj2 arthritis).ti,ab.
30	Or/16-29
31	Arthritis, Psoriatic/
32	(psoria\$ adj (arthriti\$ or arthropath\$)).tw.
33	((arthriti\$ or arthropath\$) adj psoria\$).tw.
34	Or/29-31
35	3 or 15 or 34
36	qualitative stud*.tw.

¹ Selva A, Sola I, Zhang Y, et al. Development and use of a content search strategy for retrieving studies on patients' views and preferences. Health Qual Life Outcomes 2017;15:126.

58 59

60

2		
3	37	exp Qualitative Research/
4	38	survey*.tw.
5	39	exp Data Collection/
6	40	questionnaire*.tw.
7 8	40	focus group*.tw.
8 9	42	conjoint analysis.tw.
10	43	discrete choice experiment*.tw.
11	43 44	rating task*.tw.
12	44	ranking task*.tw.
13	45 46	choice experiment*.tw.
14	40 47	decision aid*.tw.
15 16	47 48	risk attitude*.tw.
16 17	48 49	risk aversion.tw.
18	49 50	discrete choice*.tw.
19		
20	51	standard gamble.tw.
21	52	willingness to pay tw.
22	53	willingness-to-pay.tw.
23	54	decision support technique*.tw.
24	55	decision support system*.tw.
25 26	56	decision making.tw.
20	57	time trade*.tw.
28	58	exp Questionnaires/
29	59	trade off*.tw.
30	60	decision making.tw. time trade*.tw. exp Questionnaires/ trade off*.tw. stated preference*.tw. contingent valuation.tw. choice experiment.tw. best-worst scaling.tw. Q-method*.tw control preference* scale.tw. self-explicated conjoint.tw.
31	61	contingent valuation.tw.
32	62	choice experiment.tw.
33	63	best-worst scaling.tw.
34 35	64	Q-method*.tw
36	65	control preference* scale.tw.
37	66	self-explicated conjoint.tw.
38	67	Start* known efficac*.tw.
39	68	threshold technique.tw.
40	69	constant sum scal*.tw.
41	70	repertory grid method.tw.
42 43	71	exp Analytic Hierarchy Process/
43 44	72	swing weight* tw.
45	73	visual analog* scale.tw.
46	74	allocat* of point*.tw.
47	75	outcome prioriti* tool.tw.
48	76	measure of value.tw.
49	77	preference trial.tw.
50	78	grounded theory/ or qualitative research/
51 52	79	(qualitative* or focus group* or interview* or mixed method* or mixed-method* or
52 53		content analysis or thematic analysis or phenomenological study or ethnograph* or
55		interpretive description or narrative* or semi-structured or unstructured or face-to-face
55		or constant comparative or participant observation or audio recorded).mp.
56		
57		

1		
2		
3	80	px.fs
4	81	or/36-80
5 6	82	exp Consumer Satisfaction/
7	83	exp Consumer Participation/
8	84	exp Patient Satisfaction/
9	85	patient perspective*.tw.
10	86	exp "Attitude of Health Personnel"/
11	87	exp Health Knowledge, Attitudes, Practice/
12	88	exp "Delivery of Health Care"/
13		
14	89	patient compliance.tw.
15	90	patient participation.tw.
16	91	patient satisfaction.tw.
17 18	92	treatment refusal.tw.
18	93	patient preference*.tw.
20	94	patient opinion*.tw.
21	95	patient belief*.tw.
22	96	patient concern*.tw.
23	97	patient perspective*.tw.
24	98	patient choice*.tw.
25	99	patient value*.tw.
26	100	patient priorit*.tw.
27	101	exp Health Priorities/
28 29	102	patient perception*.tw.
30	103	choice behavio*.tw.
31	104	patient concern*.tw. patient perspective*.tw. patient choice*.tw. patient value*.tw. patient priorit*.tw. exp Health Priorities/ patient perception*.tw. choice behavio*.tw. patient consensus.tw. exp Consensus/ (dissent and dispute*).tw. uncertaint*.tw. (utility or utilities).ti,ab. discrete choice*.tw.
32	105	exp Consensus/
33	106	(dissent and dispute*).tw.
34	107	uncertaint*.tw.
35	108	(utility or utilities).ti,ab.
36	100	discrete choice*.tw.
37	110	((patient\$ or participant\$) adj3 (participation or satisfaction or perspective\$ or
38 39	110	compliance or preference\$ or opinion\$ or belief\$ or concern\$ or choice\$ or value\$ or
40		priorit\$ or perception\$ or request\$)).tw.
41	111	or/82-110
42		35 and 81 and 111
43	112	
44	113	exp animals/ not humans.sh.
45	114	112 not 113
46		
47		
48 49		
49 50		
51		
52		
53		
54		
55		
56		
57		
58 50		
59 60		For peer review only - http://bmiopen.bmi.com/site/about/guidelines.xhtml

Appendix B. List of	variables to be extracted	1		6/bmjopen-2024-08826: cted by copyright, inclu
Variable	Explanation	Response format	Notes	Examplesg
Study characteristi	cs			or La
Method	How were the preferences elicited	Free text	Use terminology from Table 1 where possible. Include all methods if more than one used.	-Discround France experiment -Stand France direct Responses analoge Scale
Attribute selection process	How were the attributes selected	Free text		-Qualizity study -Chosen by experts
Treatments of interest	Which treatments were the focus of the study	Free text		-csDMARDs, bDMAF tofaciting
Country(s)	Which country(s) was the study conducted in	Free text	If $>$ 5 countries, summarize according to continent or geographic region. List countries alphabetically.	-Finland; weden Al training -Outpagiene clinics at o
Setting	Clinic setting or sampling framework	Free text	Describe where patients in the study were sampled from	academic centre -Outpagient clinics at academic and commun centres - Patient registry -Online pagel
Recruitment procedure	How were people recruited	Free text	Describe the method of recruitment	-In person glinic recruitment -E-mail to patients in a existing registry -Link to the study shar through pagent groups
Eligibility criteria	Eligibility criteria for	Free text	Copy verbatim from the study	ographique de

			BMJ Open	6/bmjopen-2024- cted by copyrigh
	the study		description	ht, ii
Patient Population	Health conditions of the population studied	Free text	Include the percentages if a mixed population	RA (4%) PsA (30%), Ankylesing spondylitis (25%) = 5
Sample size	Number of people who completed the survey or study	Numeric	If some participants had missing data and this is reported, record the number of people who completed the preference- elicitation aspect of the study	January 2025. E Enseignemei or uses related t
Response rate (offered)	Percentage of people who were offered the study that completed it	Numeric	In a study where people were recruited in clinic or through a registry, this would be the number approached (for example, either in person or through e-mail) who completed the study. In a study where a link to the study was posted on a patient website, it would not be possible to estimate this number.	Downloaded from http://bmjopen.bm nt Superieur (ABES) . o text and data mining, Al training, a
Response rate (consented/viewed)	Percentage of people who consented or viewed the study that completed it	Numeric	Percentage of people who consented to the study, or who started the study (for example, in the case of an e-mailed link) and completed it.	i.com/ on June 1 nd similar techn
Funding	Funding received for the study	Free text	List the funding agency or company name	-Public (funding agency) -Industry (company name) -Public and industry (company ame)
Industry affiliations of authors	Are authors employees or affiliated with a pharmaceutical	Free text	Yes/no, then list affiliation(s)	-No -Yes (company name) bio graphique trml de

Page 27	of 28
---------	-------

1 2	
3	
4 5	Statistical analy
6 7	Patient charac
8 9 10	Age
10 11 12 13 14 15 16	Sex/Gender
17	
18 19 20 21	Disease duration (years)
22 23 24 25	Disease severity
25 26	
27	Dharris al famatic
28 29	Physical function
30	
31	Ethnicity
32 33	
34	
35 36	Education
37	
38	
39 40	
41	Place of residen
42 43	
44	
45	
46 47	
17	

			BMJ Open	6/bmjopen-2024-0 cted by copyright
	company			ght,
Statistical analysis	Statistical method	Free text	List the method as stated in the	-Mixe∉logat model
Statistical analysis	used to analyse data		text	-Hierashigal bayesian
Patient characterist	· · · · · · · · · · · · · · · · · · ·	1		g f
Age	Mean or median age of study participants	Numeric	If both mean and median reported, record mean unless sample skewed	or uses re
Sex/Gender	The sex and/or gender of the participants.	Free text with percentage values	Record as recorded/ reported by the study. Include all gender categories that were response options, if available. If both sex and gender reported, describe both.	-Female (11%), male (11%), profession (0.2%), prefer with the answer (0.5%) and the added for the ad
Disease duration (years)	How many years have the people in the study had their disease	Numeric	Record as reported by the study. In mixed populations, record for each disease, if available	-10.7 m Bm -5.5 (Registration -5.3 (PsA)
Disease severity	Measures of disease severity, relevant to the population studied	Free text	Any validated measure of disease severity e.g., DAS28, CDAI, BASDAI. Extract all that are available.	jopen.bmj.com/ on Ju training, and similar te
Physical function	Measures of functional status	Free text	Any validated measure of disease severity e.g., HAQ-DI, PROMIS Physical Function	m/ on Jun similar teo
Ethnicity	Ethnicity of study participants	Free text with percentage values	Record as reported by the study	-Caucasian (55%); Black (20%) gHispanic (10%); other (5%)
Education	Education level of study participants	Free text with percentage values	Record as reported by the study	-Greater than high-school (55%)
Place of residence	Any details on the	Free text	Only record if directly reported	-Urban (7 %); rural (25%)

			BMJ Open	cted by copyright -Immigrand / refugee/
of participants	location of participants (e.g., urban/rural)	with percentage values	by the study i.e., do not assume that if the study is conducted at an academic centre, the participants are urban.	vulnerzolychoused.
Health literacy	Any measure of the health literacy of participants	Free text	Record as reported by the study. Some tools for measuring are here.	or uses re
Additional patient characteristics relevant for the study	Any additional characteristics relevant to the study	Free text	For example, a study may have a particular focus on a subgroup of patients and could report those characteristics here if not otherwise captured above.	2025. Downloade Inement Superie lated to text and
			those characteristics here if not otherwise captured above.	<pre>' on 15 January 2025. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Age Enseignement Superieur (ABES) . Iding for uses related to text and data mining, Al training, and similar technologies.</pre>

om http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l ABES) . a mining, Al training, and similar technologies.

Patient preferences for drug therapy in inflammatory arthritis: protocol for a living systematic review and evidence map to inform clinical practice guidelines

Journal:	BMJ Open
Manuscript ID	bmjopen-2024-088267.R1
Article Type:	Protocol
Date Submitted by the Author:	26-Nov-2024
Complete List of Authors:	Saadat, Pakeezah; University of Toronto, Institute of Health Policy, Management, and Evaluation Bansback, Nick; The University of British Columbia, School of Population and Public Health; Arthritis Research Canada Falahee, Marie; University of Birmingham, Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences; University Hospitals Birmingham NHS Foundation Trust, NIHR Birmingham Biomedical Research Centre Hiligsmann , Mickaël ; Maastricht University, Department of Health Services Research, CAPHRI Care and Public Health research Institute Tugwell, Peter; University of Ottawa Faculty of Medicine, Department of Medicine; Ottawa Hospital Research Institute Clinical Epidemiology Program Buchbinder, Rachelle; Monash University, Musculoskeletal Health and Wiser Health Care Units, School of Public Health and Preventive Medicine Whittle, Samuel; Monash University, School of Public Health and Preventive Medicine; Queen Elizabeth Hospital, Rheumatology Unit Richards, Dawn P.; Canadian Arthritis Patient Alliance Proulx, Laurie ; Canadian Arthritis Patient Alliance Schunemann, Holger; McMaster University, Department of Health Research Methods, Evidence and Impact; McMaster University, Department of Medicine; Humanitas University, Department of Biomedical Sciences Alonso-Coello, Pablo; Instituto de Investigacion Biomedica, Centro GRADE Barcelona Nieuwlaat, Robby; McMaster University, Department of Medicine; McMaster University, Michael G. DeGroote Cochrane Canada & McMaster GRADE Centres; McMaster University, Department of Medicine; McMaster University, Michael G. DeGroote Cochrane Canada & McMaster GRADE Centres; McMaster University, Department of Medicine; McMaster University, Michael G. DeGroote Cochrane Canada & McMaster GRADE Centres; McMaster University, Department of Medicine; McMaster University, Michael G. DeGroote Cochrane Canada & McMaster GRADE Centres; McMaster University, Department of Medicine; McMaster University, Michael G. DeGroote Cochrane Canada & McMaste

	Hazlewood, Glen; University of Calgary Cumming School of Medicine, Departments of Medicine and Community Health Sciences; University of Calgary Cumming School of Medicine, McCaig Institute for Bone and Joint Health; Arthritis Research Canada
Primary Subject Heading :	Rheumatology
Secondary Subject Heading:	Health services research, Patient-centred medicine
Keywords:	Patients, RHEUMATOLOGY, Systematic Review

SCHOLARONE[™] Manuscripts

BMJ Open: first published as 10.1136/bmjopen-2024-088267 on 15 January 2025. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

2	
3	Patient preferences for drug therapy in inflammatory arthritis: protocol for a living systematic
4	
5	and the second sectod second sectod for the description of the difference
6	review and evidence map to inform clinical practice guidelines
7	
8	Pakeezah Saadat, ¹ pakeezah.saadat@mail.utoronto.ca
9	Nick Bansback, ² nick.bansback@ubc.ca
10	Marie Falahee, ³ m.falahee@bham.ac.uk
11 12	Mickael Hiligsmann, ⁴ m.hiligsmann@maastrichtuniversity.nl
12	Peter Tugwell, ⁵ ptugwell@uottawa.ca
13	Rachelle Buchbinder, ⁶ rachelle.buchbinder@monash.edu
15	Samuel Whittle, ⁷ samuelwhittle@gmail.com
16	Dawn P Richards, ⁸ dawn.p.richards@gmail.com
17	Laurie Proulx, ⁸ laurieproulx@bell.net
18	
19	Holger Schunemann, ^{9,10} holger.schunemann@mcmaster.ca
20	Pablo Alonso Coello, ¹¹ palonso@santpau.cat
21	Robby Nieuwlaat, ^{10,12} <u>nieuwlr@mcmaster.ca</u>
22	Wojtek Wiercioch, ^{10,12} wierciww@mcmaster.ca
23	Simon Kuper, ¹³ <u>simon.kuper97@gmail.com</u>
24	Jordi Pardo Pardo, ¹⁴ jpardo@uottawa.ca
25	Glen S Hazlewood ¹⁵ gshazlew@ucalgary.ca
26	
27	¹ Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada
28	² School of Population and Public Health, University of British Columbia, BC, Canada; Arthritis Research
29	Canada, Richmond, BC, Canada
30	³ Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental
31	Sciences, University of Birmingham, Birmingham, UK; NIHR Birmingham Biomedical Research Centre,
32	
33	University Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, UK
34	⁴ Department of Health Services Research, CAPHRI Care and Public Health research Institute, Maastricht
35	University, Netherlands
36	⁵ Department of Medicine, University of Ottawa Faculty of Medicine, Ottawa, ON, Canada; Clinical
37	Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada
38	⁶ Musculoskeletal Health and Wiser Health Care Units, School of Public Health and Preventive Medicine,
39 40	Monash University, Melbourne, Australia
40 41	⁷ School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia;
42	Rheumatology Unit, Queen Elizabeth Hospital, Adelaide, Australia
43	⁸ Canadian Arthritis Patient Alliance, Toronto, ON, Canada
44	⁹ Department of Health Research Methods, Evidence and Impact, McMaster University, Health Sciences
45	Centre, Hamilton, ON, Canada
46	¹⁰ Department of Medicine, McMaster University, Health Sciences Centre, Hamilton, ON L8S 4K1,
47	•
48	Canada; Department of Biomedical Sciences, Humanitas University, Milano, Italy
49	¹¹ Centro GRADE Barcelona, Instituto de Investigacion Biomedica (IIB Sant Pau), Barcelona, Spain
50	¹² World Health Organization Collaborating Center for Infectious Diseases, Research Methods and
51	Recommendations, Michael G. DeGroote Cochrane Canada & McMaster GRADE Centres; McMaster
52	University, Hamilton, ON, Canada
53	¹³ Faculty of Health, Medicine and Life Sciences, Maastricht University, Germany
54	¹⁴ Cochrane Musculoskeletal, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
55	
56	
57	
58	
59	
60	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1 2 3 4 5 6 7	¹⁵ Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada; Arthritis Research Canada, Richmond, BC, Canada; McCaig Institute for Bone and Joint Health, Calgary, Canada
8 9 10	Correspondence to:
11 12	Glen S Hazlewood
13 14 15	3280 Hospital Dr NW, 3AA10 HRIC, Calgary, AB T2N4Z6, Canada
16 17 18	gshazlew@ucalgary.ca
19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51	gshazlew@ucalgary.ca
52 53 54 55 56 57 58 59 60	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open: first published as 10.1136/bmjopen-2024-088267 on 15 January 2025. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES)

Enseignement Superieur (ABES). Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

ABSTRACT

Introduction: The pharmacological management of inflammatory arthritis often requires choices that involve trade-offs between benefits, risks, and other attributes such as administration route, frequency and cost. This living systematic review aims to inform international clinical guidelines on inflammatory arthritis by creating an evidence map of patient preference studies concerning the trade-offs in pharmacological management of inflammatory arthritis.

Methods and analysis: We will include published and peer-reviewed full-text studies in any language that quantitatively assess preferences of patients for the pharmacological management of inflammatory arthritis (rheumatoid arthritis, spondyloarthritis and juvenile idiopathic arthritis). Studies must use either stated or revealed preference methods to assess preferences and provide a quantitative assessment of relevant characteristics, such as benefits, risks, costs, and process attributes. Articles will identified through Medline and EMBASE database searches from inception using search terms that combine keywords and subject headings for inflammatory arthritis and preference-based methods, and a search in the Health Preference Study and Technology Registry using keywords for the populations of interest. Two independent reviewers will perform abstract and full-text screening. Risk of bias will be assessed using the GRADE risk of bias tool. An evidence map will be generated to summarize included studies and their assessments of each trade-off. The search will be conducted every 6 months with new studies added to the inventory.

Ethics and dissemination: Ethics approval is not required. Results from the base review will be published in a peer-reviewed journal and findings will be presented at conferences. In the living

BMJ Open

model, we will publish updates and datasets on an Open Science Framework page, with periodic updates in peer-reviewed journals.

Keywords: inflammatory arthritis, patient preference, trade-off, living systematic review

STRENGTHS AND LIMITATIONS OF THIS STUDY

- This living systematic review of patient preference studies will inform international clinical guidelines for inflammatory arthritis.
- Biannual updates will be conducted to promptly integrate emerging evidence, facilitating the maintenance of up-to-date clinical guidelines for inflammatory arthritis.
- Since the field is still evolving, the search strategy and data presentation will be adapted to incorporate newly emerging evidence.
- We will not meta-analyze the relative importance of each attribute as quantitative synthesis poses a challenge due to significant heterogeneity in study designs and attributes.

BMJ Open: first published as 10.1136/bmjopen-2024-088267 on 15 January 2025. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) .

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

INTRODUCTION

Treatment choices in inflammatory arthritis nearly always involve trade-offs. People living with inflammatory arthritis need to choose between treatments that can differ in their benefits, risks, and other characteristics such as route of administration, frequency, and cost. For example, in rheumatoid arthritis, "triple therapy" with methotrexate, sulfasalazine and hydroxychloroquine has additional burden in terms of more pills, potentially more adverse effects, but an improved chance of a treatment response over methotrexate alone ¹². Tofacitinib, a Janus Kinase (JAK) inhibitor, has been shown to have a higher risk of cardiovascular adverse events and certain malignancies in people at risk for cardiovascular events ³, but is available as a pill and is an effective option for many patients. For people with psoriatic arthritis, certain treatments may work better for different disease manifestations, such as skin disease or enthesitis, and this needs to be balanced against the control of their joint disease ⁴⁵. Corticosteroids offer rapid improvement for many patients with inflammatory arthritis, but long-term use is associated with multiple risks ⁶. Understanding patient preferences for these trade-offs is important to guide patient-centered care.

Patient preferences can be assessed or measured in multiple ways. Qualitative approaches can help understand how patients approach the decision-making process and the relevant considerations for a given healthcare decision ⁷. Quantitative approaches provide numerical estimates of patient preferences for different treatments or treatment attributes, including risks and benefits and other considerations, such as route of administration or cost ⁸⁹. Quantitative methods can be categorized into revealed preference methods that measure

which treatment people choose when presented with an actual choice, or stated preference methods that ask patients to rate, rank, or choose between hypothetical treatment options or attributes. Stated preference methods can be further categorized according to different frameworks ^{8 10}. Revealed preference methods, where actual choices of participants are recorded are challenging, as real-world choices are often influenced by the healthcare providers' recommendations or restrictions imposed by insurance plans. Hence, most studies use stated preference methods.

When developing clinical practice guidelines, it is important to understand patient preferences for the relevant trade-offs. Under the GRADE approach, patient values and preferences are a key consideration in the Evidence to Decision framework, when deciding on the direction and strength of a recommendation ¹¹. While not often done, a systematic review of patient preference studies is recommended to inform these judgements ¹². Quantitative estimates of patient preferences are desired, as guideline panels need to consider which outcomes or other attributes are most important and by how much. When a guideline panel is confident that based on the balance of benefits and harms nearly all patients would choose a particular course of action then a strong recommendation can be made. Otherwise, a conditional recommendation is made, either for or against the treatment. BMJ Open: first published as 10.1136/bmjopen-2024-088267 on 15 January 2025. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) .

Enseignement Superieur (ABES). Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

We have recently started living clinical guidelines for inflammatory arthritis in both Canada ^{13 14} and Australia ¹⁵⁻¹⁷. In a living clinical practice guideline, treatment recommendations are kept up to date as new evidence emerges¹⁸. Within an entire guideline, individual recommendations

BMJ Open: first published as 10.1136/bmjopen-2024-088267 on 15 January 2025. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

may remain stable, while others may be updated in a living mode through living systematic reviews of the risks and benefits, which we have initiated for inflammatory arthritis ¹⁹. Each time a recommendation is added, or new evidence emerges, guideline panels need to either make or update their judgements regarding the balance of risks and benefits. In a living model, this requires regular updates of the evidence on patient preferences. New preference studies may have been published, and treatments may have new attributes, such as newly discovered risks. For example, in our inflammatory arthritis guidelines, our recommendation for choices of treatment after an inadequate response to anti-TNF therapy ^{14 15} required an update to our prior systematic review on patient preferences ^{20 21}, given the risks of malignancy and cardiovascular events with JAK inhibitors. We did not find any studies that measured preferences for these trade-offs, but this evidence will likely emerge over time.

The aim of this systematic review will be to develop a living evidence map of patient preference studies as they relate to the treatment of inflammatory arthritis. By "evidence map" we mean a catalogue of studies that are characterized in terms of their characteristics and methods used, risk of bias, and which outcomes or other treatment attributes they included. We do not intend to summarize or meta-analyze the relative importance of each attribute, which is often challenging due to study heterogeneity. Rather, the intention is that guideline developers can use the evidence map to identify and review the studies relevant to their context to help inform clinical guideline recommendations.

METHODS AND ANALYSIS

BMJ Open

This protocol adheres to the PRISMA-P checklist,²² which is available in the supplementary material.

Eligibility criteria

Population

We will include any study that provides a quantitative assessment of patients' preferences for the management of inflammatory arthritis. Inflammatory arthritis includes rheumatoid arthritis, juvenile idiopathic arthritis, and spondyloarthritis, as defined by the study authors. Spondyloarthritis includes psoriatic arthritis, ankylosing spondylitis, reactive arthritis, enteropathic arthritis, and axial and/or peripheral spondyloarthritis not otherwise classified. We will include studies that have at least 75% of the included participants with inflammatory arthritis.

Outcomes

To be included, a study must include a quantitative assessment of the importance of attributes relevant to the pharmacologic and non-pharmacologic management of inflammatory arthritis. This includes treatment benefits, risks, and process attributes. Process attributes include any aspect related to care delivery, such as route and frequency of administration, access to care, and costs. Preferences may be assessed for attributes separately, or together, as would be the case when presenting patients with a 'real-world' choice between treatment options that differ across multiple characteristics (i.e., in revealed preference studies). We will exclude studies that exclusively provide an estimate of patients' health-related quality of life (HRQOL). HRQOL measures the value a patient places on their current health state and not their preference for potential treatment outcomes or attributes ^{23 24}.

BMJ Open: first published as 10.1136/bmjopen-2024-088267 on 15 January 2025. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de Enseignement Superieur (ABES)

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

BMJ Open

Study design

We will include any published and peer-reviewed full-text study in any language that assessed preferences using stated-preference methods ¹⁰ (where participants are asked their preferences for hypothetical choices) or revealed-preference methods (where the actual choices of patients are observed after being presented with a decision-aid)⁸. We will exclude abstracts, pre-print articles and studies that have not been peer-reviewed. The statedpreference methods categorized by Soekhai et al. ¹⁰ consist of four distinct categories (**Table 1**). Discrete-choice experiments examine trade-offs between attributes and their alternatives given a series of choice sets. Ranking methods are used to elicit an order of attributes and their alternatives through ranking exercises, such as best-worst scaling. Indifference methods ask people to make a choice between staying in a given health state for the rest of their life versus a return to full health with a shortened life expectancy (time trade-off) or a gamble with a chance of returning to full health but also a chance of immediate death (standard gamble). The thresholds (life expectancy or chance of death) are manipulated until the point of indifference is found. Rating methods ask people to choose the strength of their preference using a labeled scale.

$\begin{array}{c}1\\2\\3\\4\\5\\6\\7\\8\\9\\10\\11\\2\\13\\14\\15\\16\\17\\8\\19\\20\\22\\23\\24\\25\\26\\27\\28\\29\\30\\1\\23\\34\\35\\36\\37\\38\\9\\0\\41\\24\\34\\45\\6\\47\\8\\9\\0\\1\\52\\3\\3\\6\\7\\8\\9\\0\\1\\2\\23\\3\\4\\5\\6\\7\\8\\9\\0\\1\\2\\2\\3\\3\\4\\5\\5\\6\\7\\8\\9\\0\\1\\2\\2\\3\\3\\6\\7\\8\\9\\0\\1\\2\\3\\3\\6\\7\\8\\9\\0\\1\\2\\3\\3\\6\\7\\8\\9\\0\\1\\2\\3\\3\\6\\7\\8\\9\\0\\1\\2\\3\\3\\6\\7\\8\\9\\0\\1\\2\\3\\3\\6\\7\\8\\9\\0\\1\\2\\3\\3\\6\\7\\8\\9\\0\\1\\2\\3\\3\\6\\7\\8\\9\\0\\1\\2\\3\\3\\6\\7\\8\\9\\0\\1\\2\\3\\3\\6\\7\\8\\9\\0\\1\\2\\3\\3\\8\\3\\9\\0\\1\\2\\3\\3\\8\\3\\8\\9\\0\\1\\2\\3\\3\\8\\3\\0\\1\\2\\3\\3\\8\\1\\2\\3\\3\\8\\3\\0\\1\\2\\3\\3\\8\\3\\0\\1\\2\\3\\3\\8\\3\\0\\1\\2\\3\\3\\8\\3\\0\\1\\2\\3\\3\\8\\3\\0\\1\\2\\3\\3\\1\\2\\3\\3\\1\\2\\3\\3\\3\\1\\2\\3\\3\\3\\3\\1\\2\\3\\3\\3\\3$	
49 50 51 52	

Table 1. Inventory of patient-preference methods, adapted from Soekhai et al ¹⁰

Category	Method
Discrete-choice-based methods	Discrete choice experiment/Best-worst scaling (type 3)
	Adaptive conjoint analysis
Ranking methods	Qualitative discriminant process
	Q-methodology
	Control preferences scale
	Best-worst scaling (type 1 & 2)
•	Self-explicated conjoint
Indifference methods	Standard gamble
	Time trade-off
	Person trade-off
	Starting known efficacy
	Test trade-off
	(Probabilistic) threshold technique
	Contingent valuation
Rating methods	Constant sum scaling
	Repertory grid method
	Analytic hierarchy process
	Swing weighting
	Visual analog scale
	Allocation of points
	Outcome prioritization tool
	Measure of value
Revealed preferences	Patient preference trials
	Direct questions in clinical trials

Living review considerations: If new preference-based approaches are identified or developed over time, these will be added to the eligibility criteria. Our search (described below) is also designed to identify qualitative studies, which would allow us to expand the scope of work in the future.

Information sources and search strategy

BMJ Open: first published as 10.1136/bmjopen-2024-088267 on 15 January 2025. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) .

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

We will search the following databases from inception: Medline In Process and Other Nonindexed Citations, and EMBASE (Excerta Medica Database). The search strategy is presented in **Appendix A** and combines keywords and subject headings for inflammatory arthritis and preference-based methods. The MEDLINE and EMBASE inflammatory arthritis filters were derived from Cochrane reviews and adapted for the other databases. The preference-based method filter was derived from Selva et al ²⁵ and supplemented with additional filters to capture all methods in Table 1, as well as qualitative studies. Additionally, we will search the Health Preference Study and Technology Registry (HPSTR; <u>https://hpstr.org/</u>), a web-based registry of health preference studies and technologies, using keywords for each population of interest (defined above).

Living review considerations: The search filters will be reviewed periodically and updated as needed, particularly if new validated filters for preference studies are published that suit our purpose. For the base review, the search will be conducted once, then updated prior to publication, after which the review will transition to a living mode. In the living mode, the search will be updated every 6 months, with the frequency adjusted as needed based on the usefulness and feasibility.

Article screening

The titles and abstracts of all records will first be screened for eligibility independently by two reviewers. Any record that either reviewer marks as unclear or included will proceed to full-text review. Full-text review will also be done by pairs of reviewers working independently. Any disagreement at the full-text stage will be discussed between reviewers and with senior reviewer(s) as necessary. At the full-text stage, articles will be excluded in the following

BMJ Open

hierarchy: wrong publication type (e.g. pre-print, abstract); wrong population; wrong study design (not a preference-elicitation method); preferences for other aspects of care (e.g., diagnostic approaches). Articles in a different language will be translated into English. An example PRISMA flow-chart is presented in **Figure 1**.

Living review considerations: We will explore the incorporation of technologies to improve the efficiency of the article screening process, including automation, machine learning and crowd sourcing. We have employed these tools in other reviews of interventions ^{19 26}, but to our knowledge they have not yet been developed for patient preference literature. It is our hope that the results of our review could be used to develop automated approaches for the screening of records. We will flag potentially eligible qualitative studies in the correct population, which would allow us to expand the scope of work in the future without having to rescreen all records.

BMJ Open: first published as 10.1136/bmjopen-2024-088267 on 15 January 2025. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Data extraction

Study data will be extracted independently by two team members. From each study we will extract relevant study and participant characteristics as listed in **Appendix B** if reported. Study characteristics include details on the population of interest, setting, response rate, recruitment strategy, funding, statistical analysis used, attribute selection process, and preference-elicitation methods. Participant characteristics include age, sex/gender, disease duration and severity, health literacy and sociodemographic characteristics, particularly those that would identify patient populations at risk for inequities in care. In prior studies, we have identified the following seven priority populations for guidelines in rheumatoid arthritis ^{27 28}: rural and remote residents, Indigenous Peoples, elderly persons with frailty, first-generation immigrants and

BMJ Open: first published as 10.1136/bmjopen-2024-088267 on 15 January 2025. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de Enseignement Superieur (ABES)

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

refugees, persons of low socioeconomic status or who are vulnerably housed, sex and gender diverse populations, and Black Canadians (added since our original framework²⁹). For each study, we will extract the attributes and levels evaluated, including a short description and the actual description presented in the survey to participants. The results of the study will be extracted as the estimated value for each attribute value, including the point estimate (mean/median), scale, and measure of variability. If this data is not presented it will calculate from the available data, if possible. Otherwise, we will extract the data as reported by the study (e.g. relative importance, ranks of attribute importance). We will extract measures of variability in the following order depending on availability: standard deviations (SDs), standard errors (SEs), 95% confidence intervals (Cis) or credible intervals (CrI), and exact P-values with the statistical test used. Data screening and extraction will be done via Covidence systematic review software (Veritas Health Innovation, Melbourne, Australia, available at www.covidence.org). Living review considerations: Depending on the volume of studies identified, the timing of data extraction for each study may need to be staged, prioritizing those studies that are most relevant to inform our living guidelines. We will include a table of studies pending data extraction and risk of bias assessment in the review.

<u>Risk of bias</u>

The risk of bias in each study will be assessed using the GRADE risk of bias tool for value and preference studies, which has been developed and validated, and is being finalized for publication. Assessment will be done independently by two team members and any discrepancies will be resolved through consensus.

BMJ Open

Living review considerations: If preferred risk of bias tools change over time, these will be incorporated in the review.

Data presentation

Study characteristics will be summarized descriptively in a table. An evidence map will be generated that summarizes the current literature in terms of which available studies assess each trade-off. An example is included in **Table 2**. The rows and columns will contain all attributes assessed. Attributes will be grouped into categories by two independent reviewers with help from a senior reviewer, if needed. Each cell will list the study(s) that included those attributes. Studies that include absolute anchors of attribute importance (e.g. measured on a 0-1 scale, where 0 represents death and 1 represents full health), such as a standard gamble, time trade-off or visual analogue scales, will be included in the bottom row. This would allow guideline panels to easily identify potential studies that would be relevant for their purpose and help identify gaps in the evidence.

Living review considerations: We will explore the value of including additional information within each cell of the evidence map (e.g., sample size and risk of bias), and alternative ways of summarizing the data to guideline panels, including interactive evidence maps that would provide more flexibility.

Example of the ev	Bene		Ris			tes Process
-	Remission	Pain reduction	GI side effects	Serious side	Route of	Cost
				effects	delivery	
Remission		-	-	-	-	
Pain reduction	[Study IDs]	-	-	-	-	
GI side effects	[Study IDs]	[Study IDs]	-	-	-	
Serious side effects	[Study IDs]	[Study IDs]	[Study IDs]	-	-	
 Route of delivery	[Study IDs]	[Study IDs]	[Study IDs]	[Study IDs]	[Study IDs]	Cost
Cost	[Study IDs]	[Study IDs]	[Study IDs]	[Study IDs]	[Study IDs]	
 Absolute anchor of importance	[Study IDs]	[Study IDs]	[Study IDs]	[Study IDs]	[Study IDs]	[Stu
						(Stu

22

26 27

29

Patient and public involvement

This protocol was reviewed and refined with feedback from our patient partners, Dawn P Richards and Laurie Proulx, who are individuals living with rheumatoid arthritis/juvenile idiopathic arthritis.

ETHICS AND DISSEMINATION

Ethics approval is not required. Results from the base review will be published in a peerreviewed journal and findings will be presented at conferences. In the living model, we will publish updates and datasets on an Open Science Framework page, with periodic updates in peer-reviewed journals. BMJ Open: first published as 10.1136/bmjopen-2024-088267 on 15 January 2025. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) .

data mining, AI training, and similar technologies

Protected by copyright, including for uses related to text



Contributors

GSH is the guarantor. GSH conceptualized the study, and designed and reviewed the protocol with PS. PS and GSH drafted the study, defined the concepts, search strategy, data extraction process, methodological appraisal, and statistical analysis of the included studies. NB, MF, MH, PT, RB, SW, DPR, LP, HS, PAC, RB, WW, SK, and JPP provided critical insights. All authors have approved and contributed to the final written manuscript.

Funding

This protocol received no specific grant from any funding agency in the public, commercial or not-for-profit sectors. RB is supported by an Australian National Health and Medical Research Council (NHMRC) Investigator Fellowship (APP1194483). SW is supported by an Australia and New Zealand Musculoskeletal (ANZMUSC) Clinical Trial Network Practitioner Fellowship and by a grant from The Hospital Research Foundation Group.

Competing interests

All authors declare no competing interests.

Protected by copyright, including for uses related to text and

data mining, AI training, and similar technologies

4 5

6 7

8

9

10

11

12 13

14

15

16

17

18 19

20

21

22

23 24

25

26

27

28

29 30

31

32

33

34 35

36

37

38

39

40 41

42

43

44

45 46

47

48

49

50

51 52

53

54

55

56 57 58

REFERENCES

- Hazlewood GS, Barnabe C, Tomlinson G, et al. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis. *BMJ* 2016;353:i1777. doi: 10.1136/bmj.i1777 [published Online First: 2016/04/23]
- Hazlewood GS, Barnabe C, Tomlinson G, et al. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: A network meta-analysis. *Cochrane Database Syst Rev* 2016(8):CD010227. doi: 10.1002/14651858.CD010227.pub2 [published Online First: 2016/08/30]
 - Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. *N Engl J Med* 2022;386(4):316-26. doi: 10.1056/NEJMoa2109927 [published Online First: 2022/01/27]
 - Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol 2022;18(8):465-79. doi: 10.1038/s41584-022-00798-0 [published Online First: 2022/06/28]
 - Singh JA, Guyatt G, Ogdie A, et al. Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Rheumatol 2019;71(1):5-32. doi: 10.1002/art.40726 [published Online First: 2018/12/01]
 - Rice JB, White AG, Scarpati LM, et al. Long-term Systemic Corticosteroid Exposure: A Systematic Literature Review. *Clin Ther* 2017;39(11):2216-29. doi: 10.1016/j.clinthera.2017.09.011 [published Online First: 2017/10/23]
 - Gooberman-Hill R. Qualitative approaches to understanding patient preferences. *Patient* 2012;5(4):215-23. doi: 10.1007/BF03262494 [published Online First: 2012/09/26]
 - 8. Medical device Innovation Consortium (MDIC). Medical device Innovation Consortium (MDIC) Patient Centered Benefit-Risk Project Report: A Framework for Incorporating Information on Patient Preferences Regarding Benefit and Risk into Regulatory Assessments of New Medical Technology 2015 [updated March 11, 2022. Available from: https://mdic.org/project/patient-centered-benefit-risk-pcbr/ accessed 5 Sept 2023.
 - Hazlewood GS. Measuring Patient Preferences: An Overview of Methods with a Focus on Discrete Choice Experiments. *Rheumatic Diseases Clinics of North America* 2018;44(2):337-47. doi: <u>https://dx.doi.org/10.1016/j.rdc.2018.01.009</u>
 - Soekhai V, Whichello C, Levitan B, et al. Methods for exploring and eliciting patient preferences in the medical product lifecycle: a literature review. *Drug Discov Today* 2019;24(7):1324-31. doi: 10.1016/j.drudis.2019.05.001 [published Online First: 2019/05/12]
 - Montori VM, Brito JP, Murad MH. The optimal practice of evidence-based medicine: incorporating patient preferences in practice guidelines. *JAMA* 2013;310(23):2503-4. doi: 10.1001/jama.2013.281422 [published Online First: 2013/10/30]

Andrews JC, Schunemann HJ, Oxman AD, et al. GRADE guidelines: 15. Going from 12. evidence to recommendation-determinants of a recommendation's direction and strength. J Clin Epidemiol 2013;66(7):726-35. doi: 10.1016/j.jclinepi.2013.02.003 [published Online First: 2013/04/11] 13. Hazlewood GS, Pardo JP, Barnabe C, et al. Canadian Rheumatology Association living guidelines for the pharmacological management of rheumatoid arthritis with diseasemodifying anti-rheumatic drugs. Journal of Rheumatology 2022;15:15. doi: https://dx.doi.org/10.3899/jrheum.220209 14. Hazlewood GS, Pardo JP, Barnabe C, et al. Canadian Rheumatology Association living guidelines for the pharmacological management of rheumatoid arthritis with diseasemodifying anti-rheumatic drugs 2022 [version 1.0] [Available from: https://app.magicapp.org/#/guideline/7554 accessed May 31, 2024 [version 2.1]. 15. Australia & New Zealand Musculoskeletal Clinical Trials Network (ANZMUSC). An Australian Living Guideline for the Pharmacological Management of Inflammatory Arthritis 2023 [version 2.14] [Available from: https://app.magicapp.org/#/guideline/LqRV3n accessed June 16 Version 2.14. 16. Buchbinder R, Glennon V, Johnston RV, et al. Australian recommendations on perioperative use of disease-modifying anti-rheumatic drugs in people with inflammatory arthritis undergoing elective surgery. Intern Med J 2023 doi: 10.1111/imj.16073 [published Online First: 2023/04/18] 17. Whittle SL, Glennon V, Johnston RV, et al. Australian recommendations on tapering of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in inflammatory arthritis. Intern Med J 2022;52(10):1799-805. doi: 10.1111/imj.15816 [published Online First: 2022/05/15] 18. El Mikati IK, Khabsa J, Harb T, et al. A Framework for the Development of Living Practice Guidelines in Health Care. Ann Intern Med 2022;175(8):1154-60. doi: 10.7326/M22-0514 [published Online First: 2022/07/06] 19. Hazlewood GS, Whittle SL, Kamso MM, et al. Disease-modifying anti-rheumatic drugs for rheumatoid arthritis: a systematic review and network meta-analysis. Cochrane Database of Systematic Reviews 2020(3) doi: 10.1002/14651858.CD013562 20. Simons G, Caplan J, DiSantostefano RL, et al. Systematic review of quantitative preference studies of treatments for rheumatoid arthritis among patients and at-risk populations. Arthritis Res Ther 2022;24(1):55. doi: 10.1186/s13075-021-02707-4 [published Online First: 2022/02/24] 21. Durand C, Eldoma M, Marshall DA, et al. Patient Preferences for Disease-modifying Antirheumatic Drug Treatment in Rheumatoid Arthritis: A Systematic Review. Journal of Rheumatology 2020;47(2):176-87. doi: 10.3899/jrheum.181165 22. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4(1):1. doi: 10.1186/2046-4053-4-1 [published Online First: 2015/01/03] 23. Purnell TS, Joy S, Little E, et al. Patient preferences for noninsulin diabetes medications: a systematic review. Diabetes Care 2014;37(7):2055-62. doi: 10.2337/dc13-2527 [published Online First: 2014/06/26] For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1 2 3

4

5

6 7

8

9

10

11

12 13

14

15

16

17

18 19

20

21

22

23 24

25

26

27

28

29 30

31

32

33

34 35

36

37

38

39

40 41

42

43

44

45 46

47

48

49

50

51 52

53

54

BMJ Open

- Hazlewood GS. Measuring Patient Preferences: An Overview of Methods with a Focus on Discrete Choice Experiments. *Rheum Dis Clin North Am* 2018;44(2):337-47. doi: 10.1016/j.rdc.2018.01.009 [published Online First: 2018/04/07]
 Solva A, Sola L, Zhang X, et al. Development and use of a content coarch strategy for
 - Selva A, Sola I, Zhang Y, et al. Development and use of a content search strategy for retrieving studies on patients' views and preferences. *Health Qual Life Outcomes* 2017;15(1):126. doi: 10.1186/s12955-017-0698-5 [published Online First: 2017/08/31]
 - 26. Lee C, Thomas M, Ejaredar M, et al. Crowdsourcing trainees in a living systematic review provided valuable experiential learning opportunities: a mixed-methods study. *J Clin Epidemiol* 2022;147:142-50. doi: 10.1016/j.jclinepi.2022.03.019 [published Online First: 2022/04/02]
 - 27. Pianarosa E, Hsiao R, Thomas M, et al. Supporting Equity Through Rheumatoid Arthritis Treatment Guidelines: The Development of Logic Models for Six Populations at Risk for Inequitable Outcomes in Canada. *Journal of Rheumatology* 2020;47(7):1083-84.
 - 28. Barnabe C, Pianarosa E, Hazlewood G. Informing the GRADE evidence to decision process with health equity considerations: demonstration from the Canadian rheumatoid arthritis care context. *J Clin Epidemiol* 2021;138:147-55. doi: 10.1016/j.jclinepi.2021.06.013 [published Online First: 2021/06/24]
 - 29. Thomas M, Barnabe C, Kleissen T, et al. Rheumatoid Arthritis Care Experiences of Black People Living in Canada: A Qualitative Study to Inform Health Service Improvements. *Arthritis Care Res (Hoboken)* 2023 doi: 10.1002/acr.25278 [published Online First: 2023/12/11]

FIGURE LEGENDS

Figure 1. PRISMA flow diagram for the living systematic review of patient preference studies in inflammatory arthritis

r the living




Figure 1. PRISMA flow diagram for the living systematic review of patient preference studies in inflammatory

arthritis

(n =)

(n =)

Reports of included studies

 Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Table of Contents	
Appendix A. Search strategy (adapted from Selva et al, 2017)	2
Appendix B. List of variables to be extracted	5

to beet terien only

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Appendix A. MEDLINE Search strategy (adapted from Selva et al, 2017) ¹ # Query 1 exp arthritis, rheumatoid/ 2 ((rheumatoid or reumatic) or reumatic or reumatic or reumatic or reumatic or nodule*)).tw. 3 1 or 2 4 exp Arthritis, Juvenile Rheumatoid/ 5 JIA.tw 6 (juvenile adj2 arthritis).tw. 7 or/4-6 8 enthesitis.tw. 9 Arthritis, Psoriatic/ 10 oligoarthritis.tw. 21 to rigath or adolescent* or infan*).tw. 3 11 and 12 11 mores or adolescent* or infan*).tw. 13 11 and 12 14 limit 11 to (infant or child or preschool child <1 to 6 years> or school child <7 to 12 years> or adolescent <13 to 17 years>) 15 13 or 14 16 Spondylarthritis.ti, ab. 29 spondyloarthritis.ti, ab. 20 spondyloarthritis.ti, ab. 21 spondyloarthritis.ti, ab. 22 spondyloarthritis.ti, ab. 23 SpondylithropathS.ti, ab. 24 ankylosing spondylitis.ti, ab. <t< th=""><th>1</th><th></th><th></th></t<>	1		
Appendix A. MEDLINE Scarch strategy (adapted from Selva et al, 2017)1#Query1exp arthritis, theumatoid/2((rheumatoid or reumatioid or reumatic or reumatic or reumatic or rodule')), itw.31 or 24exp Arthritis, Juvenile Rheumatoid/5JLA.tw6(juvenile adj2 arthritis), tw.7or/4-68enthesitis.tw.9Arthritis, Psoriatic/10oligoarthritis, tw.11or(%-10)12(child' or adolescent* or infan*), tw.1311 and 1214limit 11 to (infant or child or preschool child <1 to 6 years> or school child <7 to 121513 or 1416Spondylarthritis, ti, ab.17spondylarthritis, ti, ab.18spondylarthritis, ti, ab.19Spondylarthritis, ti, ab.21spondylarthritis, ti, ab.22Spondylarthripapathies/23Spondylitis, Ankylosing/24ankylosing spondylitis, ti, ab.25spondylitis, fash.26((axial adj (SpA or disease or arthritis)) or axial joint disease), ti, ab.23Spondylitis, fash.24ankylosing spondylitis or sacroilitis), ti, ab.25spondylitis, or afteropath\$), tw.26((axial adj (SpA or disease or arthritis)) or axial joint disease), ti, ab.23Spondylitis, fash.24ankylosing spondylitis or sacroilitis), ti, ab.25spondylitis, fash.26((axial adj (SpA or disease or ar	2		
5Appendix A. MEDLINE Search strategy (adapted from Selva et al, 2017)17#Query81exp arthritis, rhcumatoid/91exp arthritis, rhcumatoid or revmatio or reumatic or revmatic or rhcumate' or rewmatrint') adj3 (arthrit* or artrit* or diseas* or condition* or nodule*)).tw.1331 or 2144exp Arthritis, Juvenile Rhcumatoid/15JJA.tw(juvenile adj2 arthritis).tw.166(juvenile adj2 arthritis).tw.170or/4-618enthesitis.tw.10oligoarthritis.tw.11or/8-1012(child* or adolescent* or infan*).tw.1311 and 1214limit 11 to (infant or child or preschool child <1 to 6 years> or school child <7 to 12 years>)1513 or 1416Spondylarthritis.ti, ab.17spondylarthritis.ti, ab.18spondylarthripathies/2916Spondylarthripathies/20spondylarthripathies/212222spondylarthropath\$.ti, ab.231324ankylosing spondylitis.ti, ab.25spondylitis.ti, ab.261427renthesiti, ti, ab.2829291620spondylarthropath\$.ti, ab.212122spondylarthropath\$.ti, ab.232124ankylosing spondylitis.ti, ab.252526sacrolititis or sacrolititis	3		
#Query91exp arthritis, rheumatoid/101(rheumatioid or reumatoid or revmatoid or rheumatic or reumatic or reheumat* or reumat* or revmatrit*) adj3 (arthrit* or artrit* or diseas* or condition* or nodule*).tw.111or 2124exp Arthritis, Juvenile Rheumatoid/131or 214exp Arthritis, Juvenile Rheumatoid/15JIA.tw16(juvenile adj2 arthritis).tw.17or/4-618enthesitis.tw.29Arthritis, Psoriatic/10oligoarthritis.tw.21(child* or adolescent* or infan*).tw.22(14)231224limit 11 to (infant or child or preschool child <1 to 6 years> or school child <7 to 1225years> or adolescent <13 to 17 years>)261527years> or adolescent <13 to 17 years>)281529spondylarthritis.ti, ab.20spondylarthritis.ti, ab.2114221523SpondylarthropathS.ti, ab.24ankylosing spondylitis.ti, ab.25spondyloing spondylitis.ti, ab.26gendyloing thropathS.ti, ab.27sacroilitis/ or (sacroilitis or sacroilitis)) or axial joint disease).ti, ab.28sacroilitis/ or (sacroilitis or sacroilitis).ti, ab.29(peripheral adj2 arthritis).ti, ab.29(gentritis or arthropath\$)).tw.20(goriaš adj (arthritiš or arthropath\$)).tw.21<			
7#Query91exp arthritis, rheumatoid /102((rheumatoid or reumatoid or rheumatic or reumatic or a nodule*)).tw.131 or 214exp Arthritis, Juvenile Rheumatoid/15J LA.tw16(juvenile adj2 arthritis).tw.17or/4-618enthesitis.tw.19810oligoarthritis.tw.211022(child* or adolescent* or infan*).tw.2311 and 1224limit 11 to (infant or child or preschool child <1 to 6 years> or school child <7 to 12251311 and 12261427years> or adolescent <13 to 17 years>)281513 or 1429Spondylarthritis/iab.311739spondylarthropathS.ti,ab.32183319342039spondylarthropathS.ti,ab.35213924412642ankylosing spondylitis.ti,ab.432044454647484940414142434444454546464748<		Арро	endix A. MEDLINE Search strategy (adapted from Selva et al, 2017) ¹
8 \mathbf{Cutry} 91cxp arthritis, rheumatoid /102((rheumatoid or reumatoid or revmatoid or rheumatic or reumatic or rodule*)).tw.11rheumat* or reumat* or revmarthrit*) adj3 (arthrit* or artrit* or diseas* or condition* or nodule*)).tw.131or 214exp Arthritis, Juvenile Rheumatoid/15JIA.tw16(juvenile adj2 arthritis).tw.17or/4-618enthesitis.tw.19820921oligoarthritis.tw.22102311 and 1224limit 11 to (infant or child or preschool child <1 to 6 years> or school child <7 to 1227years> or adolescent <13 to 17 years>)28152930 rl 429Spondylarthritis.i, ab.20spondylarthritis.ti, ab.211522spondylarthritis.ti, ab.23SpondylarthropathS.ti, ab.24spondylarthropathS.ti, ab.25spondylarthropathS.ti, ab.26spondylarthropathS.ti, ab.27spondylarthropathS.ti, ab.28sacroilitis/ or (sacroilitis or sacroilitis)) or axial joint disease).ti, ab.29spondylitis.tw.20spondylitis.tw.211422for disease or arthritis)) or axial joint disease).ti, ab.23spondylarthropathS.ti, ab.24gathritis.for arthropathS)).tw.25spondylitis or (sacroilitis or sacroilitis).ti, ab. <td< th=""><th></th><th></th><th></th></td<>			
8 1 exp arthritis, rheumatoid/ 10 2 ((theumatoid or reumatoid or revmatic or reumatic or revmatic or rheumatic or reumatic or revmatic or rheumatic or revmatic or nodule*)).tw. 11 1 072 14 exp Arthritis, Juvenile Rheumatoid/ 15 JIA.tw 16 (juvenile adj2 arthritis).tw. 17 6 (juvenile adj2 arthritis).tw. 18 or/4-6 19 8 enthesitis.tw. 20 9 Arthritis, Psoriatic/ 21 10 olgoarthritis.tw. 22 11 or/8-10 23 12 (child* or adolescent* or infan*).tw. 24 11 and 12 25 13 or 14 26 14 limit 11 to (infant or child or preschool child <1 to 6 years> or school child <7 to 12 years> 26 15 3 or 14 27 years> or adolescent <13 to 17 years> 28 spondylarthritis.ti, ab. 29 16 Spondylarthritis.ti, ab. 21 spondyloarthropathis/i, ab. 22 Spondylitis, Ankylosing/ 23 <t< th=""><th></th><th>#</th><th>Ouerv</th></t<>		#	Ouerv
102((fheumatoid or reumatoid or reumatic or			- •
the umat* or reumat* or revmatthrit*) adj3 (arthrit* or artrit* or diseas* or condition* or nodule*)).tw.131 or 214exp Arthritis, Juvenile Rheumatoid/15JLA.tw16Giuvenile adj2 arthritis).tw.17618cnthesitis.tw.29Arthritis, Psoriatic/21102102211231224122513261427years> or adolescent* or infan*).tw.2815291620Spondylarthritis ti, ab.21102216231224132513261427years> or adolescent <13 to 17 years>)2815291620spondylarthritis ti, ab.211822spondylarthritis ti, ab.232124atkylosing yondylitis.ti, ab.25spondylarthropathS.ti, ab.262227spondylitis.ti, ab.2823292420spondylitis.ti, ab.212522spondylitis.ti, ab.232424adiy(SpA or disease or arthritis)) or axial joint disease).ti, ab.29429(peripheral adj2 arthritis).ti, ab.29420spondylitis.ti, ab.2125 <td></td> <td></td> <td></td>			
12nodule*)).tw.131 or 214exp Arthritis, Juvenile Rheumatoid/15JIA.tw16(juvenile adj2 arthritis).tw.17618ord-4.6198198209Arthritis, Psoriatic/21102210231124122513261427ycars> or adolescent* or infan*).tw.28152913 or 14201420142110 (infant or child or preschool child <1 to 6 years> or school child <7 to 12		2	
1331 or 2144exp Arthritis, Juvenile Rheumatoid/15JIA.tw16(juvenile adj2 arthritis).tw.17618enthesitis.tw.29921102211231224122513261427142814291620Spondylarthritis.ti,ab.21172216232024172513261327years> or adolescent <13 to 17 years>)2815291620Spondylarthritis.ti,ab.201321spondylarthritis.ti,ab.221823SpondylarthropathS.ti,ab.24ankylosing yondylitis.ti,ab.252626Spondylitis, Ankylosing/2738283929429620Spondylitis.ti,ab.203921spondylitis.ti,ab.223923Spondylitis.ti,ab.243025spondylitis.ti,ab.26427enthesitis.ti,ab.2839294293920ankylosing spondylitis.ti,ab.213022Spondylitis.ti,ab.			
11111exp Arthritis, Juvenile Rheumatoid/1JIA.tw1(juvenile adj2 arthritis).tw.1or/4-61enthesitis.tw.292Arthritis, Psoriatic/21102211231124122513261427years> or adolescent* or infan*).tw.28132914201420142110 (infant or child or preschool child <1 to 6 years> or school child <7 to 12		2	
154Exp Attituts, diverse Kitelihaldity16JIA.tw17(juvenile adj2 arthritis).tw.18 $or/4-6$ 19819810oligoarthritis.tw.20921102211231124122513261427years> or adolescent* or infan*).tw.281329142013 or 14291629292013 or 14291629292030213022302313 or 1429162952013 or 14291620Spondylarthritis.ti,ab.2131231724spondylarthritis.ti,ab.2529263127spondylarthropaths.ti,ab.282029292930203021302230233024ankylosing spondylitis.ti,ab.253026292714283229152915291629162017201821302219 </td <td></td> <td></td> <td></td>			
165JIA.W176(juvenile adj2 arthritis).tw.176(juvenile adj2 arthritis).tw.187or/4-6198enthesitis.tw.209Arthritis, Psoriatic/2110oligoarthritis.tw.2211or/8-102312(child* or adolescent* or infan*).tw.2412(child* or adolescent * or infan*).tw.251311 and 122614limit 11 to (infant or child or preschool child <1 to 6 years> or school child <7 to 12			exp Arthritis, Juvenile Rheumatoid/
176(juvenle adj2 arthritis).tw.187or/4-6198enthesitis.tw.209Arthritis, Psoriatic/2110oligoarthritis.tw.2211or/8-102311 and 12(child* or adolescent* or infan*).tw.2412(child* or adolescent < 13 to 17 years>)2513 or 14112614limit 11 to (infant or child or preschool child <1 to 6 years> or school child <7 to 12		5	JIA.tw
187or/4-6198enthesitis.tw.209Arthritis, Psoriatic/2110oligoarthritis.tw.2211or/8-102312(child* or adolescent* or infan*).tw.2412(child* or adolescent* or infan*).tw.251311 and 122614limit 11 to (infant or child or preschool child <1 to 6 years> or school child <7 to 12		6	(juvenile adj2 arthritis).tw.
198enthesitis.tw.209Arthritis, Psoriatic/2110oligoarthritis.tw.2211 $or/8-10$ 2312(child* or adolescent* or infan*).tw.2412(child* or adolescent* or infan*).tw.251311 and 122614limit 11 to (infant or child or preschool child <1 to 6 years> or school child <7 to 12		7	
209Arthritis, Psoriatic/2110oligoarthritis.tw.2211or/8-102312(child* or adolescent* or infan*).tw.2412(child* or adolescent* or infan*).tw.251311 and 122614limit 11 to (infant or child or preschool child <1 to 6 years> or school child <7 to 12		8	enthesitis tw
2110oligoarthritis.tw.2211or/8-102312(child* or adolescent* or infan*).tw.2412(child* or adolescent* or infan*).tw.251311 and 122614limit 11 to (infant or child or preschool child <1 to 6 years> or school child <7 to 12			
2211or/8-102312(child* or adolescent* or infan*).tw.2412(child* or adolescent* or infan*).tw.251311 and 122614limit 11 to (infant or child or preschool child <1 to 6 years> or school child <7 to 12			
22_{4} 12(child* or adolescent* or infan*).tw. 13 11 and 12 14 limit 11 to (infant or child or preschool child <1 to 6 years> or school child <7 to 12 years> or adolescent <13 to 17 years>) 15 13 or 14 29 16Spondylarthritis.ti, ab. 17 spondylarthritis.ti, ab. 17 spondylarthritis.ti, ab. 18 spondylarthritis.ti, ab. 19 Spondylarthropaths.ti, ab. 21 spondylarthropaths.ti, ab. 22 Spondylarthropaths.ti, ab. 31 9 32 Spondylarthropaths.ti, ab. 32 18 spondylarthropaths.ti, ab. 34 20 spondylitis/ 34 20 spondylitis.ti, ab. 34 20 spondylitis.ti, ab. 35 21 spondylitis.ti, ab. 36 22 spondylitis.ti, ab. 37 23 spondylitis.ti, ab. 40 25 spondylitis.ti, ab. 41 26 ((axial adj (SpA or disease or arthritis)) or axial joint disease).ti, ab. 42 27 erthesitis.ti, ab. 43 8 sacroilitis/ or (sacroilitis or sacroilitis).ti, ab. 44 29 (peripheral adj2 arthritis).ti, ab. 45 30 (r/16-29 46 30 (rathritis or arthropath\$)).tw. 48 32 (psoriafs adj (arthritis or arthropath\$)).tw. 49 40 (r/29-31 41 51 (arthritis or arthropath\$) adj psoria\$).tw. 52 36 (qualitative stud*.tw. 53 30 r 15 or 34 (arthritis or	22		
221311 and 122614limit 11 to (infant or child or preschool child <1 to 6 years> or school child <7 to 12 years> or adolescent <13 to 17 years>)281513 or 142916Spondylarthritis.ti,ab.3017spondylarthritis.ti,ab.3117spondylarthropathies/3218spondylarthropaths.ti,ab.3319Spondylarthropaths.ti,ab.3420spondylarthropaths.ti,ab.3521spondylarthropaths.ti,ab.3622Spondylitis, Ankylosing/3723Spondylitis.ti,ab.3824ankylosing spondylitis.ti,ab.3924ankylosing spondylitis.ti,ab.4025spondylitis.ti,ab.4126((axial adj (SpA or disease or arthritis)) or axial joint disease).ti,ab.4227enthesitis.ti,ab.4328sacroilitis/ or (sacroilitis) or sacroilitis).ti,ab.4429(peripheral adj2 arthritis).ti,ab.4530Or/16-294632(psoria\$ adj (arthriti\$ or arthropath\$)).tw.4731Arthriti\$ or arthropath\$).tw.4832(pacia\$ adj (arthriti\$ or arthropath\$)).tw.4933or /29-3151353 or 15 or 345236qualitative stud*.tw.	23		
 limit 11 to (infant or child or preschool child <1 to 6 years> or school child <7 to 12 years> or adolescent <13 to 17 years>) 13 or 14 Spondylarthritis/ spondylarthritis.ti,ab. spondylarthropath\$.ti,ab. spondylarthropath\$.ti,ab. spondylarthropath\$.ti,ab. spondylarthropath\$.ti,ab. spondylarthropath\$.ti,ab. spondylarthropath\$.ti,ab. spondylitis.ti,ab. spondylitis.ti,ab. spondylitis.ti,ab. spondylarthropath\$.ti,ab. (axial adj (SpA or disease or arthritis)) or axial joint disease).ti,ab. ((axial adj (SpA or disease or arthritis)) or axial joint disease).ti,ab. ((axial adj (SpA or disease or arthritis)).ti,ab. (peripheral adj2 arthritis).ti,ab. (peripheral adj2 arthritis).ti,ab. (poria\$ adj (arthriti\$ or arthropath\$)).tw. ((arthriti\$ or arthropath\$) adj psoria\$).tw. or/29-31 or 15 or 34 qualitative stud*.tw. 	24		
27years> or adolescent <13 to 17 years>)281513 or 142916Spondylarthritis/3017spondylarthritis.ti,ab.3117spondylarthritis.ti,ab.3218spondylarthropathies/3319Spondylarthropath\$.ti,ab.3420spondylarthropath\$.ti,ab.3521spondylarthropath\$.ti,ab.3622Spondylitis/3723Spondylitis, Ankylosing/3824ankylosing spondylitis.ti,ab.3924ankylosing spondylitis.ti,ab.4025spondylitis.ti,ab.4126((axial adj (SpA or disease or arthritis)) or axial joint disease).ti,ab.4227enthesitis.ti,ab.4328sacroiliitis/ or (sacroiliitis or sacroilitis).ti,ab.4429(peripheral adj2 arthritis).ti,ab.4530Or/16-294631Arthriti\$ or arthropath\$)).tw.4731Arthriti\$ or arthropath\$) adj psoria\$).tw.5034Or/29-3151353 or 15 or 345236qualitative stud*.tw.	25		
281513 or 142916Spondylarthritis/3017spondylarthritis.ti,ab.3118spondylarthropathis/3319Spondylarthropaths.ti,ab.3420spondylarthropaths.ti,ab.3521spondyloarthropaths.ti,ab.3622Spondylitis/3723Spondylitis, Ankylosing/3824ankylosing spondylitis.ti,ab.3924ankylosing spondylitis.ti,ab.4025spondylitis.ti,ab.4126((axial adj (SpA or disease or arthritis)) or axial joint disease).ti,ab.4227enthesitis.ti,ab.4328sacroiliitis/ or (sacroiliitis or sacroilitis).ti,ab.4429(peripheral adj2 arthritis).ti,ab.4530Or/16-294631Arthritis, Psoriatic/4832(psoria\$ adj (arthriti\$ or arthropath\$)).tw.4933((arthriti\$ or arthropath\$) adj psoria\$).tw.5034Or/29-3151353 or 15 or 345236qualitative stud*.tw.	26	14	
2916Spondylarthritis/3017spondylarthritis.ti,ab.3117spondylarthritis.ti,ab.3218spondylarthropathies/3319Spondylarthropaths.ti,ab.3420spondylarthropaths.ti,ab.3521spondylarthropaths.ti,ab.3622Spondylitis, Ankylosing/3723Spondylitis, Ankylosing/3824ankylosing spondylitis.ti,ab.3924ankylosing spondylitis.ti,ab.4025spondylitis.ti,ab.4126((axial adj (SpA or disease or arthritis)) or axial joint disease).ti,ab.4227enthesitis.ti,ab.4328sacroiliitis/ or (sacroiliitis or sacroilitis).ti,ab.4429(peripheral adj2 arthritis).ti,ab.4530Or/16-294631Arthritis, Psoriatic/4832(psoria% adj (arthriti\$ or arthropath\$)).tw.4933((arthriti\$ or arthropath\$) adj psoria\$).tw.5034Or/29-3151353 or 15 or 345236qualitative stud*.tw.	27		years> or adolescent <13 to 17 years>)
 Spondylarithits, i, ab. spondylarithits, i, ab. spondylarithits, i, ab. spondylarithropathies/ spondylarithropathies/ spondylarithropath\$, ii, ab. scorollitis, or (sacrollitis or sacrollitis).ti, ab. (peripheral adj2 arthritis).ti, ab. (peripheral adj2 arthritis).ti, ab. (arthritis, Psoriatic/ (psoria\$ adj (arthriti\$ or arthropath\$)).tw. (arthritis or arthropath\$) adj psoria\$).tw. 34 Or/29-31 35 3 or 15 or 34 qualitative stud*.tw. 		15	13 or 14
3017spondylarthritis.ti,ab. 31 18spondyloarthritis.ti,ab. 32 19Spondylarthropathis/ 34 20spondylarthropath\$.ti,ab. 34 20spondyloarthropath\$.ti,ab. 34 20spondyloarthropath\$.ti,ab. 35 21spondyloarthropath\$.ti,ab. 36 22Spondylitis/ 37 23Spondylitis, Ankylosing/ 38 24ankylosing spondylitis.ti,ab. 39 24ankylosing spondylitis.ti,ab. 40 25spondylitis.ti,ab. 41 26((axial adj (SpA or disease or arthritis)) or axial joint disease).ti,ab. 42 27enthesitis.ti,ab. 43 28sacroiliitis or sacroilitis or sacroilitis).ti,ab. 44 29(peripheral adj2 arthritis).ti,ab. 44 29(peripheral adj2 arthritis).ti,ab. 45 30Or/16-29 46 32(psoria\$ adj (arthriti\$ or arthropath\$)).tw. 49 33((arthriti\$ or arthropath\$) adj psoria\$).tw. 50 34Or/29-31 51 353 or 15 or 34 52 36qualitative stud*.tw. 54		16	Spondylarthritis/
3118spondyloarthritis.ti,ab.3219Spondylarthropathies/3319Spondylarthropath\$.ti,ab.3420spondylarthropath\$.ti,ab.3521spondyloarthropath\$.ti,ab.3622Spondylitis/3723Spondylitis, Ankylosing/3824ankylosing spondylitis.ti,ab.3924ankylosing spondylitis.ti,ab.4025spondylitis.ti,ab.4126((axial adj (SpA or disease or arthritis)) or axial joint disease).ti,ab.4227enthesitis.ti,ab.4328sacroilitis/ or (sacroilitis or sacroilitis).ti,ab.4429(peripheral adj2 arthritis).ti,ab.4530Or/16-294631Arthritis, Psoriatic/4832(psoria\$ adj (arthriti\$ or arthropath\$)).tw.4933((arthriti\$ or arthropath\$) adj psoria\$).tw.5034Or/29-3151353 or 15 or 346236qualitative stud*.tw.		17	
3319Spondylarthropathies/ 34 20spondylarthropath\$.ti,ab. 35 21spondyloarthropath\$.ti,ab. 36 22Spondylitis/ 37 23Spondylitis, Ankylosing/ 38 24ankylosing spondylitis.ti,ab. 39 24ankylosing spondylitis.ti,ab. 40 25spondylitis.ti,ab. 41 26((axial adj (SpA or disease or arthritis)) or axial joint disease).ti,ab. 42 27enthesitis.ti,ab. 43 28sacroilitis/ or (sacroilitis or sacroilitis).ti,ab. 44 29(peripheral adj2 arthritis).ti,ab. 44 29(peripheral adj2 arthritis).ti,ab. 45 30Or/16-29 46 31Arthritis, Psoriatic/ 48 32(psoria\$ adj (arthriti\$ or arthropath\$)).tw. 49 33((arthriti\$ or arthropath\$) adj psoria\$).tw. 50 34Or/29-31 51 353 or 15 or 34 52 36qualitative stud*.tw.			
3420spondylarthropath\$.ti,ab.3521spondyloarthropath\$.ti,ab.3622Spondylitis/3723Spondylitis, Ankylosing/3824ankylosing spondylitis.ti,ab.3924ankylosing spondylitis.ti,ab.4025spondylitis.ti,ab.4126((axial adj (SpA or disease or arthritis)) or axial joint disease).ti,ab.4227enthesitis.ti,ab.4328sacroiliitis/ or (sacroiliitis or sacroilitis).ti,ab.4429(peripheral adj2 arthritis).ti,ab.4530Or/16-294631Arthritis, Psoriatic/4832(psoria\$ adj (arthriti\$ or arthropath\$)).tw.4933((arthriti\$ or arthropath\$) adj psoria\$).tw.5034Or/29-3151353 or 15 or 345236qualitative stud*.tw.			
 35 21 spondyloarthropath\$.ti,ab. 36 22 Spondylitis/ 37 23 Spondylitis, Ankylosing/ 38 24 ankylosing spondylitis.ti,ab. 39 25 spondylitis.ti,ab. 40 25 spondylitis.ti,ab. 41 26 ((axial adj (SpA or disease or arthritis)) or axial joint disease).ti,ab. 42 27 enthesitis.ti,ab. 43 28 sacroiliitis/ or (sacroiliitis or sacroilitis).ti,ab. 44 29 (peripheral adj2 arthritis).ti,ab. 45 30 Or/16-29 46 31 Arthritis, Psoriatic/ 48 32 (psoria\$ adj (arthriti\$ or arthropath\$)).tw. 49 33 ((arthriti\$ or arthropath\$) adj psoria\$).tw. 50 34 Or/29-31 51 35 3 or 15 or 34 54			
 Spondylitis/ Spondylitis, Ankylosing/ ankylosing spondylitis.ti,ab. spondylitis.ti,ab. ((axial adj (SpA or disease or arthritis)) or axial joint disease).ti,ab. ((axial adj (SpA or disease or arthritis)) or axial joint disease).ti,ab. enthesitis.ti,ab. sacroiliitis/ or (sacroiliitis or sacroilitis).ti,ab. (peripheral adj2 arthritis).ti,ab. (peripheral adj2 arthritis).ti,ab. Or/16-29 Arthritis, Psoriatic/ ((arthritis or arthropath\$)).tw. ((arthritis or arthropath\$)).tw. or (y29-31 or 15 or 34 qualitative stud*.tw. 			
 Spondylitis, Ankylosing/ Spondylitis, Ankylosing/ ankylosing spondylitis.ti,ab. spondylitis.ti,ab. ((axial adj (SpA or disease or arthritis)) or axial joint disease).ti,ab. ((axial adj (SpA or disease or arthritis)) or axial joint disease).ti,ab. enthesitis.ti,ab. sacroiliitis/ or (sacroiliitis or sacroilitis).ti,ab. (peripheral adj2 arthritis).ti,ab. (peripheral adj2 arthritis).ti,ab. Or/16-29 Arthritis, Psoriatic/ (psoria\$ adj (arthriti\$ or arthropath\$)).tw. ((arthriti\$ or arthropath\$) adj psoria\$).tw. Or/29-31 3 or 15 or 34 qualitative stud*.tw. 			
 Spondylitis, Ankytosing/ ankylosing spondylitis.ti,ab. spondylitis.ti,ab. ((axial adj (SpA or disease or arthritis)) or axial joint disease).ti,ab. ((axial adj (SpA or disease or arthritis)) or axial joint disease).ti,ab. enthesitis.ti,ab. sacroiliitis/ or (sacroiliitis or sacroilitis).ti,ab. (peripheral adj2 arthritis).ti,ab. (peripheral adj2 arthritis).ti,ab. Or/16-29 Arthritis, Psoriatic/ (psoria\$ adj (arthriti\$ or arthropath\$)).tw. ((arthriti\$ or arthropath\$) adj psoria\$).tw. Or/29-31 3 or 15 or 34 qualitative stud*.tw. 			
 ankylosing spondylitis.ti,ab. spondylitis.ti,ab. ((axial adj (SpA or disease or arthritis)) or axial joint disease).ti,ab. ((axial adj (SpA or disease or arthritis)) or axial joint disease).ti,ab. enthesitis.ti,ab. sacroiliitis/ or (sacroiliitis or sacroilitis).ti,ab. (peripheral adj2 arthritis).ti,ab. (peripheral adj2 arthritis).ti,ab. Or/16-29 Arthritis, Psoriatic/ (psoria\$ adj (arthriti\$ or arthropath\$)).tw. (arthriti\$ or arthropath\$) adj psoria\$).tw. or/29-31 or 15 or 34 qualitative stud*.tw. 			Spondylitis, Ankylosing/
 spondylitis.ti,ab. ((axial adj (SpA or disease or arthritis)) or axial joint disease).ti,ab. ((axial adj (SpA or disease or arthritis)) or axial joint disease).ti,ab. enthesitis.ti,ab. sacroiliitis/ or (sacroiliitis or sacroilitis).ti,ab. (peripheral adj2 arthritis).ti,ab. Or/16-29 Arthritis, Psoriatic/ (psoria\$ adj (arthriti\$ or arthropath\$)).tw. ((arthriti\$ or arthropath\$) adj psoria\$).tw. or/29-31 or 15 or 34 qualitative stud*.tw. 		24	
 26 ((axial adj (SpA or disease or arthritis)) or axial joint disease).ti,ab. 27 enthesitis.ti,ab. 28 sacroiliitis/ or (sacroiliitis or sacroilitis).ti,ab. 29 (peripheral adj2 arthritis).ti,ab. 30 Or/16-29 31 Arthritis, Psoriatic/ 32 (psoria\$ adj (arthriti\$ or arthropath\$)).tw. 33 ((arthriti\$ or arthropath\$) adj psoria\$).tw. 34 Or/29-31 35 3 or 15 or 34 36 qualitative stud*.tw. 		25	spondylitis.ti,ab.
$\begin{array}{cccccccccccccccccccccccccccccccccccc$		26	((axial adj (SpA or disease or arthritis)) or axial joint disease).ti,ab.
43 28 sacroiliitis/ or (sacroiliitis or sacroilitis).ti,ab. 44 29 (peripheral adj2 arthritis).ti,ab. 45 30 Or/16-29 46 31 Arthritis, Psoriatic/ 47 31 Arthritis, Psoriatic/ 48 32 (psoria\$ adj (arthriti\$ or arthropath\$)).tw. 49 33 ((arthriti\$ or arthropath\$) adj psoria\$).tw. 50 34 Or/29-31 51 35 3 or 15 or 34 52 36 qualitative stud*.tw. 53		27	
44 29 (peripheral adj2 arthritis).ti,ab. 45 30 Or/16-29 46 31 Arthritis, Psoriatic/ 47 32 (psoria\$ adj (arthriti\$ or arthropath\$)).tw. 48 32 (psoria\$ adj (arthriti\$ or arthropath\$)).tw. 49 33 ((arthriti\$ or arthropath\$) adj psoria\$).tw. 50 34 Or/29-31 51 35 3 or 15 or 34 52 36 qualitative stud*.tw. 53			
45 30 Or/16-29 46 31 Arthritis, Psoriatic/ 47 31 Arthritis, Psoriatic/ 48 32 (psoria\$ adj (arthriti\$ or arthropath\$)).tw. 49 33 ((arthriti\$ or arthropath\$) adj psoria\$).tw. 50 34 Or/29-31 51 35 3 or 15 or 34 52 36 qualitative stud*.tw. 53			
46 31 Arthritis, Psoriatic/ 47 32 (psoria\$ adj (arthriti\$ or arthropath\$)).tw. 48 32 ((arthriti\$ or arthropath\$)).tw. 49 33 ((arthriti\$ or arthropath\$) adj psoria\$).tw. 50 34 Or/29-31 51 35 3 or 15 or 34 52 36 qualitative stud*.tw. 54	45		
47 32 (psoria\$ adj (arthriti\$ or arthropath\$)).tw. 48 33 ((arthriti\$ or arthropath\$)).tw. 49 33 ((arthriti\$ or arthropath\$)) adj psoria\$).tw. 50 34 Or/29-31 51 35 3 or 15 or 34 52 36 qualitative stud*.tw. 53	46		
49 33 ((arthriti\$ or arthropath\$) adj psoria\$).tw. 50 34 Or/29-31 51 35 3 or 15 or 34 52 36 qualitative stud*.tw. 53	47		
50 34 Or/29-31 51 35 3 or 15 or 34 52 36 qualitative stud*.tw. 53	48		
51 35 3 or 15 or 34 52 36 qualitative stud*.tw. 53	49		
52 36 qualitative stud*.tw. 53			
53 54		35	3 or 15 or 34
53		36	qualitative stud*.tw.

¹ Selva A, Sola I, Zhang Y, et al. Development and use of a content search strategy for retrieving studies on patients' views and preferences. Health Qual Life Outcomes 2017;15:126.

BMJ Open: first published as 10.1136/bmjopen-2024-088267 on 15 January 2025. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

1		
1 2		
3	37	ovn Qualitativa Rosporch/
4	37	exp Qualitative Research/ survey*.tw.
5	38 39	exp Data Collection/
6	40	questionnaire*.tw.
7 8	40 41	focus group*.tw.
8 9	42	conjoint analysis.tw.
10	43	discrete choice experiment*.tw.
11	44	rating task*.tw.
12	45	ranking task*.tw.
13	46	choice experiment*.tw.
14 15	40	decision aid*.tw.
16	48	risk attitude*.tw.
17	49	risk aversion.tw.
18	50	discrete choice*.tw.
19	51	standard gamble.tw.
20	52	willingness to pay.tw.
21	53	willingness-to-pay.tw.
22 23	54	decision support technique*.tw.
23	55	decision support system* tw
25	56	decision making.tw.
26	57	time trade*.tw.
27	58	exp Questionnaires/
28	59	trade off*.tw.
29 30	60	decision making.tw. time trade*.tw. exp Questionnaires/ trade off*.tw. stated preference*.tw. contingent valuation.tw. choice experiment.tw. best-worst scaling.tw. Q-method*.tw control preference* scale.tw. self-explicated conjoint.tw.
30	61	contingent valuation.tw.
32	62	choice experiment.tw.
33	63	best-worst scaling.tw.
34	64	Q-method*.tw
35	65	control preference* scale.tw.
36 27	66	self-explicated conjoint.tw.
37 38	67	Start* known efficac*.tw.
39	68	threshold technique.tw.
40	69	constant sum scal*.tw.
41	70	repertory grid method.tw.
42	71	exp Analytic Hierarchy Process/
43	72	swing weight*.tw.
44 45	73	visual analog* scale.tw.
45	74	allocat* of point*.tw.
47	75	outcome prioriti* tool.tw.
48	76	measure of value.tw.
49	77	preference trial.tw.
50	78	grounded theory/ or qualitative research/
51 52	79	(qualitative* or focus group* or interview* or mixed method* or mixed-method* or
52		content analysis or thematic analysis or phenomenological study or ethnograph* or
54		interpretive description or narrative* or semi-structured or unstructured or face-to-face
55		or constant comparative or participant observation or audio recorded).mp.
56		
57		
58 50		

59

1		
2		
3	80	px.fs
4	81	or/36-80
5	82	exp Consumer Satisfaction/
6	82	exp Consumer Participation/
7	83 84	
8 9		exp Patient Satisfaction/
10	85	patient perspective*.tw.
11	86	exp "Attitude of Health Personnel"/
12	87	exp Health Knowledge, Attitudes, Practice/
13	88	exp "Delivery of Health Care"/
14	89	patient compliance.tw.
15	90	patient participation.tw.
16	91	patient satisfaction.tw.
17	92	treatment refusal.tw.
18 19	93	patient preference*.tw.
20	94	patient opinion*.tw.
20	95	patient belief*.tw.
22	96	patient concern*.tw.
23	97	patient perspective*.tw.
24	98	patient choice*.tw.
25	99	patient value*.tw.
26	100	patient priorit*.tw.
27 28	101	exp Health Priorities/
28	102	patient perception*.tw.
30	103	choice behavio*.tw.
31	104	patient consensus.tw.
32	105	exp Consensus/
33	106	(dissent and dispute*).tw.
34	107	uncertaint*.tw.
35	108	(utility or utilities).ti,ab.
36 37	109	discrete choice*.tw.
37	110	((patient\$ or participant\$) adj3 (participation or satisfaction or perspective\$ or
39	110	compliance or preference\$ or opinion\$ or belief\$ or concern\$ or choice\$ or value\$ or
40		priorit\$ or perception\$ or request\$)).tw.
41	111	or/82-110
42	112	35 and 81 and 111
43	112	exp animals/ not humans.sh.
44	113	112 not 113
45	114	112 1101 115
46 47		
47		
49		
50		
51		
52		
53		
54 55		
55 56		
57		
58		
50		

Page 28 of 30

3	Appendix
4	ppenui
5	X 7 L 1
6	Variable
7	
8	Study cl
9	Method
10	
11	
12	
13	
14	
15	Attribute
16	process
17	Treatme
18	interest
19	merest
20	

Appendix B. List of v	variables to be extracted	1	BMJ Open	6/bmjopen-2024-08826 cted by copyright, incl
Variable	Explanation	Response format	Notes	Exampleso
Study characteristic	cs	Tormat		i for ປະ
Method	How were the preferences elicited	Free text	Use terminology from Table 1 where possible. Include all methods if more than one used.	-Discrage for an aloge state of the state of
Attribute selection process	How were the attributes selected	Free text		-Quality study -Chose experts
Treatments of interest	Which treatments were the focus of the study	Free text		-csDMARDs, bDMARDs, tofaciting
Country(s)	Which country(s) was the study conducted in	Free text	If > 5 countries, summarize according to continent or geographic region. List countries alphabetically.	-Finland; Sweden Al trainin
Setting	Clinic setting or sampling framework	Free text	Describe where patients in the study were sampled from	-Outpatient clinics at one academic centre -Outpatient clinics at academic and community centres, -Patient registry -Online pagel
Recruitment procedure	How were people recruited	Free text	Describe the method of recruitment	-In person glinic recruitment -E-mail to atients in an existing registry -Link to the study shared through pagent groups
Eligibility criteria	Eligibility criteria for	Free text	Copy verbatim from the study	tml de

Page	29	of	3	0
------	----	----	---	---

			BMJ Open	6/bmjopen-2024- cted by copyrigh
	the study		description	088
Patient Population	Health conditions of the population studied	Free text	Include the percentages if a mixed population	RA (4%)))PsA (30%), Ankylesing spondylitis (25%)
Sample size	Number of people who completed the survey or study	Numeric	If some participants had missing data and this is reported, record the number of people who completed the preference- elicitation aspect of the study	
Response rate (offered)	Percentage of people who were offered the study that completed it	Numeric	In a study where people were recruited in clinic or through a registry, this would be the number approached (for example, either in person or through e-mail) who completed the study. In a study where a link to the study was posted on a patient website, it would not be possible to estimate this number.	January 2025. Downloaded from http://bmjopen.bm Enseignement Superieur (ABES) . or uses related to text and data mining, Al training, a
Response rate (consented/viewed)	Percentage of people who consented or viewed the study that completed it	Numeric	Percentage of people who consented to the study, or who started the study (for example, in the case of an e-mailed link) and completed it.	i.com/ on June \ nd similar techr
Funding	Funding received for the study	Free text	List the funding agency or company name	-Public (funding agency) -Industry (Rompany name -Public and industry (company ame)
Industry affiliations of authors	Are authors employees or affiliated with a pharmaceutical	Free text	Yes/no, then list affiliation(s)	-No en -Yes (company name) bliographique atml de

			BMJ Open	6/bmjopen-2024-0 cted by copyright
	company			ght, ii
Statistical analysis	Statistical method	Free text	List the method as stated in the	-Mixe log t model
	used to analyse data		text	-Hiera
Patient characterist		I		g 15
Age	Mean or median age of study participants	Numeric	If both mean and median reported, record mean unless sample skewed	January 2 Enseig
Sex/Gender	The sex and/or gender of the participants.	Free text with percentage values	Record as recorded/ reported by the study. Include all gender categories that were response options, if available. If both sex and gender reported, describe both.	-Female (11%), male (11%), mono-binary (0.2%), prefer to the answer (0.5%) and end fr
Disease duration (years)	How many years have the people in the study had their disease	Numeric	Record as reported by the study. In mixed populations, record for each disease, if available	-10.7 m BBm -5.5 (RA) 5.3 (PsA)
Disease severity	Measures of disease severity, relevant to the population studied	Free text	Any validated measure of disease severity e.g., DAS28, CDAI, BASDAI. Extract all that are available.	jopen.bmj.co training, and
Physical function	Measures of functional status	Free text	Any validated measure of disease severity e.g., HAQ-DI, PROMIS Physical Function	m/ on Jur similar teo
Ethnicity	Ethnicity of study participants	Free text with percentage values	Record as reported by the study	-Caucasian (55%); Black (20%) Hispanic (10%); other (55%)
Education	Education level of study participants	Free text with percentage values	Record as reported by the study	-Greater than high-school (55%)
Place of residence	Any details on the	Free text	Only record if directly reported	-Urban (7 %); rural (25%)

			BMJ Open	s/bmjc
				cted by copyright Immight
of participants	location of participants (e.g., urban/rural)	with percentage values	by the study i.e., do not assume that if the study is conducted at an academic centre, the participants are urban.	-Immigrand refugee/ vulnerably housed.
Health literacy	Any measure of the health literacy of participants	Free text	Record as reported by the study. Some tools for measuring are here.	
Additional patient characteristics relevant for the study	Any additional characteristics relevant to the study	Free text	For example, a study may have a particular focus on a subgroup of patients and could report those characteristics here if not	2025. Download gnement Superie lated to text and
			otherwise captured above.	njopen.bmj.co training, and s
				m/ on June 13, 20 similar technolog
				January 2025. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . r uses related to text and data mining, Al training, and similar technologies.